c5ar binding antibody and its use

专利摘要:
C5aR-BINDING ANTIBODY, ITS USE IN TREATING IMMUNOLOGICAL DISEASES AND PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT. The present invention relates to antibodies binding to the second extracellular loop of C5aR comprising specific amino acid sequences and defined herein. By binding to C5aR, antibodies inhibit C5a signaling, particularly the proinflammatory signal. The present invention also relates to the use of said antibodies in the treatment of an immune disease or disorder, such as rheumatoid arthritis (RA), psoriatic arthritis, systemic lupus erythematosus (SLE), lupus nephritis, inflammatory bowel disease (Dll), or irritable bowel syndrome and a pharmaceutical composition comprising said antibodies.
公开号:BR112013031198B1
申请号:R112013031198-3
申请日:2012-06-04
公开日:2020-10-20
发明作者:Stefan Zahn；Louise Hjerrild Zeuthen；Anker Jon Hansen；Kristian Kjaergaard；Soren Lund
申请人:Novo Nordisk A/S；
IPC主号:

专利说明:

Field of the Invention
[0001] The present invention relates to the field of therapeutic antibodies. Background
[0002] The proteolysis of each of the complementary C3-C5 proteins gives rise to cationic fragments of amino terminals with signaling molecules called anaphylatoxins. The most powerful of these, C5a, produces the broadest responses. Considering the components of the inflammatory response such as leukocyte marginalization and infiltration, the release of granule-bound proteolytic enzymes, the production of radicals derived from active nitrogen and oxygen, changes in blood flow and capillary leakage, along with the ability to contract smooth muscles, the C5a molecule is the "complete" pro-inflammatory mediator. At sub-nanomolar and nanomolar levels, the C5a molecule produces chemotaxis of all myeloid strains (neutrophils, eosinophils, and basophils, macrophages and monocytes), and causes vascular permeability that is considerably enhanced by circulating prostaglandins and leukocytes. Higher nanomolar concentrations produce degranulation and activation of NADPH oxidase. This extent of bioactivity contrasts with other inflammatory mediators. C5a is involved in the pathogenesis of several disorders including rheumatoid arthritis, psoriasis, sepsis, reperfusion injury, and adult respiratory distress syndrome (Gerard and Gerard, 1994; Murdoch and Finn, 2000).
[0003] C5a activities are mediated by binding C5a to its receptor (C5aR). C5aR belongs to the family of seven receptors coupled to the transmembrane G protein. C5aR is a high affinity receptor for C5a, with a Kd of ~ 1 nM, and is located in a number of different cell types including leukocytes. The number of receptors per cell is extremely high, up to 200,000 sites per leukocyte. The biological activation of the receptor occurs over a band that saturates the bond.
[0004] The C5aR structure follows the family of seven transmembrane receptors, with the extracellular N-terminal being followed by seven transmembrane helices connected by inter-helical domains alternating as intracellular and extracellular loops, and ending with an intracellular C-terminal domain. C5aR contains an extended extracellular N-terminal domain. This large N-terminal domain is typical of receptors coupled to the G protein that binds to peptides including IL-8 and the families of fMet-Leu-Phe (FMLP) receptors.
[0005] Inhibition of C5a responses with C5aR antagonists reduces the acute C5a-mediated inflammatory response without affecting other complementary components.
[0006] To that end, C5aR peptide antagonists and anti-C5a receptor antibodies have been previously described (Watanabe et al., 1995; Pellas et al., 1998; Konteatis et al., 1994; Kanekoe et al., 1995; Morgan et al. , 1993). For example, WO 95/00164 describes antibodies directed against an N-terminal peptide (residues 9-29) from C5aR. WO 03/062278 also describes antibodies directed against C5aR. Three of these mouse antibodies were called 7F3, 6C12, and 12D4. These antibodies have been shown to have excellent properties, such as being very effective in blocking C5a by binding to its receptor, stopping C5a-directed migration of neutrophils in vitro, and preventing inflammation in animal models. To control chronic diseases, it may be necessary to administer the antibody on successive occasions over months or years. However, a disadvantage of administering mouse antibodies is that the human immune system can generate its own antibodies directed against the mouse antibody (the HAMA response). The HAMA response can neutralize the antibodies in mice quickly by drawing them out of the blood, thereby preventing the mouse antibody from binding to its target. To prevent the development of a HAMA response, a strategy that has been adopted is to "humanize" the mouse antibody by replacing as many "foreign" residues as possible in regions of non-epitope binding with human sequences.
[0007] A major problem with humanization procedures was a loss of affinity for the antigen (Jones et al., 1986), in some cases, at least 10 times or more, especially when the antigen is a protein (Verhoeyen et al., 1988). The loss of any affinity is certainly highly undesirable. At least, it means that more of the humanized antibody will have to be injected into the patient, at a higher cost and greater risk of side effects. Even more critically, an antibody with reduced affinity may have poorer biological functions, such as complement lysis, antibody-dependent cell cytotoxicity, or virus neutralization. Although faced with these difficulties, the successful humanization of anti-human C5aR antibodies has been described in WO 2009/103113.
[0008] Several strategies have been developed over the years to further minimize the risk of any unwanted side reactions from administering antibodies to patients, which includes reducing the likelihood of forming anti-drug antibodies in patients by generating "completely" human antibodies .
[0009] Even today, the identification of antibodies suitable for therapeutic applications is a challenging task. Therefore, alternative and / or enhanced C5aR antagonists that can be used in diagnostic and / or therapeutic methods remain of high interest. summary
[00010] The present invention relates to anti-C5aR antibodies and their use for diagnostic and / or therapeutic methods. The inventors have identified a series of antibodies binding to human C5aR that are, in many respects, functionally superior to the previously described anti-C5aR antibodies.
[00011] As demonstrated here, the inventors have identified a series of human antibodies that bind to human C5aR (hC5aR) and can remove hC5a to hC5aR binding and inhibit hC5a-mediated neutrophil migration. In addition, the inventors have successfully converted non-human residues present in the framework region of one of these anti-hC5aR antibodies to human germline residues without affecting the potency of the antibody.
[00012] Furthermore, by changing the Fc region, the inventors established an anti-hC5aR antibody that does not induce phagocytosis, ADCC or CDC in vitro. The details of the invention will be clear from the description of the exemplified modalities.
[00013] One aspect of the invention relates to an antibody where the variable region of the heavy chain of said antibody comprises a sequence of CDR1, CR2 and CDR3, wherein said CDR sequences comprise one of the following groups of sequences; SEQ ID NO. 1, 2, e3, SEQ ID NO. 9, 10, and 11, SEQ ID NO. 17, 18 and 19, SEQ ID NO. 25, 26 and 27 or variants of each of the sequences where 1, 2 or 3 amino acid (s) are replaced by a different amino acid residue.
[00014] One aspect of the invention relates to an antibody where the variable region of the light chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, wherein said CDR sequences comprise one of the following groups of sequences; SEQ ID NO. 5, 6 and 7, SEQ ID NO. 13, 14 and 15, SEQ ID NO. 21, 22 and 23, SEQ ID NO. 29, 30 and 31 or variants of each of the sequences where 1, 2 or 3 amino acid (s) are replaced by a different amino acid residue.
[00015] One aspect of the invention relates to a human antibody specifically binding to hC5aR, where said antibody binds the 2nd extracellular loop of hC5aR.
[00016] One aspect of the invention relates to an antibody especially binding to hC5aR, where the Fc region of the antibody has been modified compared to the reference sequences lgG1, lgG2, lgG4 and lgG4 / G2 reducing the ability of antibodies to induce phagocytosis , ADCC and / or CDC via Fcgama receptor (FcyR) interaction. In a particular embodiment, the Fc region of the antibody is IgG1 and in a further particular embodiment, the Fc region comprises one or more of the following groups of point mutations. I) N297Q and / or II) L234A and L235E and / or III) G236R and L328R and / or IV) N297Q, L234A and L235E and / or V) N297Q, L234A, L235E and G237A and / or VI) L234A, L235E, G237A, A330S and P331S
[00017] In a further aspect, the invention relates to the use of antibodies according to the invention for the treatment of an immune disease or disorder.
[00018] In a further aspect, the invention relates to a method for the treatment of a disease or disorder comprising administering to a subject in need of treatment a therapeutic amount of an antibody as described herein.
[00019] In another aspect, the present invention provides a method for treating or preventing a disorder in an individual, the method comprising administering to the individual an antibody of the invention. In one embodiment, the disorder is an immunopathological disorder such as an autoimmune disease.
[00020] Additional aspects and modalities of the invention will be clear from the description here including exemplified modalities. It follows from the description that the invention has provided new therapeutic antibodies with various benefits and advantages as characterized here. Brief Description of Drawings
[00021] Figure 1 shows alignments of the variable regions of a selection of isolated and characterized monoclonal antibodies in the application.
[00022] Figure 2 shows the specificity of binding a selection of antibodies towards chimeras of human and mouse C5aR. The binding of 32F3A6, 35F12A2 and 35F32A3 to human / mouse chimeric C5aR compared to Ref Ab Q binding. The chimeric receptors are shown schematically. The regions derived from human and mouse C5aR are shown with a thin line and a thick line, respectively.
[00023] Figure 3 shows the alignments of the variable regions of an antibody with the light and heavy sequences of the nearest human germline antibody. "/" indicates a break in the sequence, such as between segments V, D or J.
[00024] Figure 4 shows clinical scores for three treatment groups given a single loading dose (arrow) of 0.5, 1.5 or 10 mg / kg i.p. 5 days after the inflammation established in the K / BxN-hC5aR-KO / KI serum transfer model, followed by 9 daily doses of 0.25, 0.5 or 2 mg / kg, respectively, with error bars representing ± SD . The controls received lgG1 3G12.
[00025] Figure 5 shows the expression of C5a protein in patients with osteoarthritis and psoriatic arthritis of synovial fluid (controls). The level of C5a was significantly elevated in the group of patients with psoriatic arthritis (p = 0.001; Mann-Whitney).
[00026] Figure 6 is a semi-quantitative analysis of C5aR protein expression in Crohn's disease and ulcerative colitis. The expression of C5aR protein was investigated by immunohistochemistry and analyzed by the Kruskal-Wallis test with Dunn's post-test of multiple comparisons in Prism GraphPad 5, and P <0.05 was considered significant. * P <0.05; ** P <0.01; *** P <0.001. Definitions
[00027] Unless otherwise indicated, recombinant protein, cell culture and immunological techniques used in the present invention are standard procedures, well known to those skilled in the art. Such techniques are described and explained throughout the literature in sources such as J. Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons (1984), J. Sambrook and others, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989), TA Brown (editor), Essential Molecular Biology: A Practical Approach, Volumes 1 and 2, IRL Press (1991), DM Glover and B.D. Hames (editors), DNA Cloning: A Practical Approach, Volumes 1 to 4, IRL Press (1995 and 1996), and FM Ausubel et al. (Editors), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley- Interscience (1988 , including all updates to date), Ed Harlow and David Lane (editors) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, (1988), and JE Coligan and others (editors) Current Protocols in Immunology, John Wiley and Sons (including all updates to date).
[00028] As used herein, "C5a receptor", "C5aR", "C5aRI" or "human C5aR" and variations thereof refer to the complementary human component 5 receptor 1 which is also known in the art as the anaphylatoxin receptor C5a and the CD88 antigen. C5aR belongs to the family of seven receptors coupled to the transmembrane G protein, and binds C5a (Gerard and Gerard, 1991). An example of the amino acid sequence of a human C5aR is provided in SEQ ID NO: 41, however, as one skilled in the art will be aware that there are naturally occurring allelic variants of that molecule that are also covered by the term "C5aR". The various human C5aR domains are defined as follows: Amino acids 1 to 37: extracellular N-terminal domain, Amino acids 38 to 61: transmembrane domain, Amino acids 62 to 71: intracellular domain, Amino acids 72 to 94: transmembrane domain, Amino acids 95 to 110 : extracellular domain - extracellular loop 1, Amino acids 111 to 132: transmembrane domain, Amino acids 133 to 149: intracellular domain, Amino acids 150 to 174: transmembrane domain, Amino acids 175 to 206: extracellular domain - extracellular loop 2, Amino acids 207 to 227: domain transmembrane, Amino acids 228 to 242: intracellular domain, Amino acids 243 to 264: transmembrane domain, Amino acids 265 to 283: extracellular domain - extracellular loop 3, Amino acids 284 to 307: transmembrane domain, Amino acids 308 to 350: intracellular domain - C-terminal.
[00029] The term "treatment", as used here, refers to the medical therapy of any human individual or other animal individual in need of treatment. It is expected that said individual has undergone physical examination by a doctor or veterinary medical professional, who has provided an attempted or definitive diagnosis that would indicate that the use of said specific treatment is beneficial to the health of said human or other animal individual. The time interval and the purpose of said treatment can vary from one individual to another, according to the status quo of the patient's health. Thus, said treatment can be prophylactic, palliative, symptomatic and / or curative. In terms of the present invention, prophylactic, palliative, symptomatic and / or curative treatments can represent separate aspects of the invention.
[00030] In relation to medical treatment, the term "individual", as used here, means any animal, in particular mammals, such as humans, horses, cows, cats, and dogs, and can, where appropriate, be used interchangeable with the term "patient". Preferably, the individual is a human. As used herein, the terms "treating", "treating", or "treatment" and variations thereof include administering a therapeutically effective amount of an antibody of the invention sufficient to reduce or eliminate at least one symptom of the disorder.
[00031] As used here, the terms "preventing", "preventing" or "preventing" or variations thereof, refer to protecting an individual from developing at least one symptom of a disease, or reducing the severity of a symptom of the disorder .
[00032] As used here, the term "exposing the cell" refers to providing the antibody such that it is able to contact / bind to human C5aR, since C5aR is present in the cell.
[00033] The term "50% effective concentration" (abbreviated "EC50") represents the concentration of an antibody of the invention that is required for 50% of a given effect of the molecule that the antibody is targeting (for example, inhibiting / remove the binding of human C5a to human C5aR). It is understood that a lower EC50 value corresponds to a more potent antibody.
[00034] As used here, the term "inhibition" refers to a significant reduction, and possibly to completely abolish, the defined activity. Preferably, the defined activity is reduced or inhibited by at least 50%, more preferably at least 75% and even more preferably at least 90%.
[00035] Throughout this specification, the word "understand", or variations such as "comprises", or "comprising", implies the inclusion of a particular element, integer or step, or group of elements, integers or steps, but not exclusion of any other element, integer or step, or group of elements, integers or steps.
[00036] In one embodiment, a molecule essentially consists of the defined sequence.
[00037] In another embodiment, a molecule consists of the defined sequence.
[00038] In one embodiment, the molecule, such as an antibody or DNA sequence, is an isolated molecule. The term "isolated antibody" refers to an antibody that has been separated and / or recovered from other component (s) in its natural environment and / or purified from a mixture of components in its natural environment.
[00039] The term "antibody", as called herein, includes integral antibodies and any antigen-binding fragments (i.e., "antigen-binding portion") or single strands thereof. Full-length antibodies (or whole antibodies) comprise four polypeptide chains, two heavy chains (H) and two light chains (L) interconnected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (VH) and a heavy chain constant region (CH). Each light chain is comprised of a light chain variable region (VL) and a light chain constant region (CL). The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. The variable regions of the heavy and light chains contain a binding domain that interacts with the antigen. Each light chain is comprised of a light chain variable region (abbreviated here as LCVR or VL) and a light chain constant region. The light chain constant region is comprised of a domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, called complementarity determining regions (CDR), interspersed with regions that are more conserved, called structure regions (FR).
[00040] Each VH and VL is composed of three CDRs and four FRs, arranged from the amino-terminal to the carboxy-terminal in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The antibody constant regions can mediate the binding of immunoglobulin to host tissues or factors, including various cells of the immune system (for example, effector cells) and the first component (Clq) of the classic complementary system.
[00041] As used herein, the term "antibody" is used to describe whole antibodies and any antigen-binding fragments (i.e., "antigen-binding portion") or single strands of those that specifically bind to their corresponding antigen . Examples of antigen-binding fragments include Fab, Fab ', F (ab) 2, F (ab') 2, F (ab) S, Fv (typically the VL and VH domains of a single arm of an antibody), Fv single-stranded (scFv, see, for example, Bird et al., Science 1988; 242: 42S-426; and Huston et al., PNAS 1988; 85: 5879 to 5883), dsFv, Fd fragments (typically the VH and CHI domain ), and dAb (typically a VH domain); VH, VL, VhH, and V-NAR domains; monovalent molecules comprising a single chain of VH and VL; minibodies, diabodies, triabodies, tetribodies, and kappa bodies (see, for example, III et al., Protein Eng 1997; 10: 949 to 957); Camel IgG; IgNAR; as well as one or more isolated CDRs or a paratope, where isolated CDRs or antigen-binding residues or polypeptides can be linked or linked together to form a functional antibody fragment. Various types of antibody fragments have been described or revised, for example, in Holliger and Hudson, Nat Biotechnol 2005; 2S: 1126 to 1136; W02005040219, and U.S. Patent Applications published 20050238646 and20020161201.
[00042] The term "complementarity determining region" ("CDR") or "hypervariable region", when used here, refers to the amino acid residues of an antibody that are responsible for binding to the antigen. CDRs are generally comprised of amino acid residues 24 to 34 (L1), 50 to 56 (L2) and 89 to 97 (L3) in the light chain variable domain and 31 to 35 (H1), 50 to 65 (H2) and 95 to 102 (H3) in the heavy chain variable domain; (Kabat et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242) and / or these "hypervariable loop" residues (residues 26 to 32 ( L1), 50 to 52 (L2) and 91 to 96 (L3) in the light chain variable domain and 26 to 32 (H1), 53 to 55 (H2) and 96 to 101 (H3) in the heavy chain variable domain; Chothia and Lesk, J. Mol. Biol 1987; 196: 901 to 917). Typically, the numbering of amino acid residues in this region is performed by the method described in kabat et al., Above. The phrases such as "kabat position", "kabat residue", and "according to Kabat", here refer to this numbering system for heavy chain variable domains or light chain variable domains. Using the Kabat numbering system, the actual linear amino acid sequence of a peptide may contain fewer or more amino acids corresponding to a shortening, insertion into a variable domain (FR) or CDR structure. For example, a heavy chain variable domain may include amino acid inserts (residue 52a, 52b and 52c according to Kabat) after residue 52 of CDR H2 and inserted residues (for example, residues 82a, 82b and 82c, etc. of according to Kabat) after heavy chain FR residue 82. Kabat numbering of residues can be determined for a given antibody by aligning in regions of homology of the antibody sequence with a "standard" numbered Kabat sequence.
[00043] The term "framework region" or "FR" residues refers to amino acid residues VH and VL that are not within the CDRs, as defined here.
[00044] The crystallizable fragment region ("Fc region" / "Fc domain") of an antibody is the "tail" region of an antibody that interacts with cell surface receptors called Fc receptors, as well as some proteins of the system complementary.
[00045] Monoclonal antibodies are typically made by fusing myeloma cells with spleen cells from a mouse that has been immunized with the desired antigen. Human monoclonal antibodies can be obtained from transgenic animals (for example, mice or other suitable species) encoding human antibodies. Alternatively, recombinant monoclonal antibodies can be made involving technologies, called repertoire cloning or phage display / yeast display. Recombinant antibody engineering involves using viruses or yeast to create antibodies, rather than mice.
[00046] The term "humanized antibody", as used here, refers to a chimeric human / non-human antibody that contains sequences, usually at least the minimal complementarity determining regions (CDR sequences) derived from an immunoglobulin sequence of non-human germline. A humanized antibody is thus a human immunoglobulin (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as from a mouse, rat , rabbit, or non-human primate, which has the desired specificity, affinity and ability.
[00047] Humanized antibodies that comprise at least CDR regions not derived from human germline sequences and can also be called a "chimeric antibody", if antibody light and heavy chain genes have been constructed, typically by genetic engineering, from immunoglobulin constant and variable region genes that originate from different species. For example, the variable gene segments of a mouse monoclonal antibody can be linked to human constant segments.
[00048] The term "human antibody", as used herein, is intended to include antibodies having variable regions in which both framework regions and CDR regions are derived from human germline immunoglobulin sequences. It is noted that such antibodies may, however, comprise amino acid residues that are not found in human germline sequences due to mutations occurring due to in vivo or in vitro maturation. Furthermore, if the antibody contains a constant region, the constant region is also mainly derived from human germline immunoglobulin sequences. The human antibodies of the invention may, however, include amino acid residues not encoded by human germline immunoglobulin sequences (for example, mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). On the other hand, the term "human antibody", as used here, is not intended to include antibodies or alternative antigen-binding regions in which the CDR sequences are derived from the germline of other mammalian species, such as a mouse and have subsequently been grafted in human structure sequences (see humanized antibody above). The human antibody can be a human monoclonal antibody. Such a human monoclonal antibody can be produced by a hybridoma that includes a B cell obtained from a transgenic non-human animal, for example, a transgenic mouse, having a genome comprising a human heavy chain transgene and a light chain transgene fused to an immortalized cell. Human antibodies can also be isolated from sequence libraries built on selections of human germline sequences, still diversified with natural and synthetic sequence diversity. Human antibodies can be prepared by in vitro immunization of human lymphocytes followed by transformation of the lymphocytes with Epstein-Barr virus. The sequence of the human antibody can be identified allowing the production of the antibody by recombinant methods.
[00049] Furthermore, humanized, human and fully human antibodies can comprise residues that are not found in the recipient antibody or the donor antibody. These modifications are made to further refine the performance of the antibody.
[00050] The term "antibody derivatives" refers to any modified form of the antibody, such as an antibody conjugate or other agent or antibody.
[00051] The term "antigen" refers to the molecular entity used to immunize an immunocompetent vertebrate to produce an antibody that recognizes the antigen. Here, the term antigen is used more widely and is generally intended to include target molecules that are specifically recognized by the antibody, thus including fragments or imitations of the molecule used in the immunization process to raise the antibody or such molecules used for screening by immunization and also molecules used for screening in cases where antibodies are obtained by alternative methods such as phage screening.
[00052] The term "epitope", as used here, is defined in the context of a molecular interaction between an "antigen-binding polypeptide", such as an antibody, and its corresponding "antigen". Generally, the "epitope" refers to the area or region in an antigen to which an antibody specifically binds, that is, the area or region in physical contact with the antibody. A protein epitope may comprise amino acid residues in the antigen that are directly involved in binding to the antibody (also called the immunodominant component of the epitope) and other amino acid residues, which are not directly involved in binding, such as antigen amino acid residues that they are effectively blocked by Ab (in other words, the amino acid residue is within the "solvent-excluded surface" and / or the "footprint" of the antibody). A given antigen can comprise a number of different epitopes, which can include, without limitation; linear peptide antigenic determinants, conformational antigenic determinants consisting of one or more non-contiguous amino acids located close together in the native (mature) conformation; and post-translational antigenic determinants that consist, in whole or in part, of molecular structures covalently linked to the antigen, such as carbohydrate groups.
[00053] From the fact that the epitope descriptions and definitions, depending on the epitope mapping method used, are obtained in different levels of detail, it follows that the comparison of epitope for different Abs in the same Ag can be similarly conducted in different levels of detail.
[00054] The terms "binding", "specifically binding", "binding specificity" is used here to describe the selectivity of an antibody or antigen-binding fragment thereof.
[00055] The antibodies according to the invention can specifically bind to C5aR, indicating that the antibody has significantly less affinity for other antigens, where significantly less can be such as at least 2 times less, or 5 times less or 10 times smaller. The antibody may still be species-specific, just as the antibody specifically binds to human C5aR, but not high affinity mouse C5aR.
[00056] The term "binding affinity" is used here as a measure of the strength of a non-covalent interaction between two molecules, for example, an antibody, or a fragment thereof, and an antigen. The term "binding affinity" is used to describe monovalent interactions (intrinsic activity). The binding affinity between two molecules, for example, an antibody, or a fragment thereof, and an antigen, through a monovalent interaction can be quantified by determining the dissociation constant (KD). In turn, KD can be determined by measuring the kinetics of complex formation and dissociation, for example, by the SPR method. The rate constants corresponding to the association and dissociation of a monovalent complex are called the association rate constant ka (or kon) and the dissociation rate constant Kd (or KOff), respectively. KD is related to ka and Kd through the equation KD = Kd / ka.
[00057] Furthermore, "affinity" refers to the strength of the bond between a single molecule-binding site (for example, an antibody) and a ligand (for example, an antigen). The affinity of a molecule X for a ligand Y is represented by the dissociation constant (Kd), which is the concentration of Y that is required to occupy the combination sites of half of the X molecules present in a solution. A lower Kd indicates a stronger or higher affinity interaction, and a lower concentration of ligand is required to occupy these sites. Similarly, the specificity of an interaction can be assessed by determining and comparing the KD value for the interaction of interest, such as a specific interaction between an antibody and an antigen, with the KD value of an interaction not of interest.
[00058] Typically, the KD for the antibody with respect to the target will be 2 times, preferably 5 times, more preferably 10 times less than KD with respect to the other non-target molecule, such as unrelated material or accompanying material in the environment or control . More preferably, the KD will be 50 times less, such as 100 times less, or 200 times less; even more preferably 500 times smaller, such as 1,000 times smaller or 10,000 times smaller.
[00059] The value of this dissociation constant can be determined directly by well-known methods, and can be computed even for complex mixtures by methods such as those, for example, presented by Caceei and others (Byte 9: 340 to 362, 1984) . For example, KD can be established using a double-filter nitrocellulose filter binding assay as described by Wong & Lohman (Proc. Natl. Acad. Sci. USA 90, 5428 to 5432, 1983). Other standard assays to assess the binding capacity of tai ligands such as antibodies towards targets are known in the art - including, for example, ELISA, Western Blot, RIA, and flow cytometry analysis. The binding kinetics and binding affinity of the antibody can also be evaluated by standard assays known in the art, such as SPR.
[00060] A competitive binding assay can be conducted in which the binding of the antibody to the target is compared to the binding of the target by another ligand of that target, such as another antibody. The concentration, at which 50% inhibition occurs, is known as Ki. Under ideal conditions, Ki is equivalent to KD. The Ki value will never be less than the KD, so the Ki measurement can be conveniently substituted to provide an upper limit for KD.
[00061] As one skilled in the art will appreciate, "greed" refers to the total force of interaction between two molecules, such as an antibody and antigen. Greed depends on both the affinity and the valence of interactions.
[00062] Additional assays to determine the functionality of a given antibody may include cell-based assays that are specific to the given antigen and the effect of binding to the antibody.
[00063] The term "identity", as known in the art, refers to a relationship between the sequences of two or more polypeptides, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relationship between the polypeptides, as determined by the number of matches between the sequences of two or more amino acid residues.
[00064] "Identity" measures the percentage of identical matches between the smallest of two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (ie, "algorithms"). The identity of the polypeptides can be readily calculated by known methods. Such methods include, but are not limited to, those described in Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York, 1991; and Carillo et al., SIAM J. Applied Math. 48, 1073 (1988).
[00065] The preferred methods for determining identity are designed to provide the greatest match between the tested strings. Methods for determining identity are described in publicly available computer programs. Preferred computer program methods for determining identity between two sequences include the GCG program package, including GAP (Devereux et al., Nucl. Acid. Res. 12, 387 (1984); Genetics Computer Group, University of Wisconsin, Madison , Wis.), BLASTP, BLASTN, and FASTA (Altschul et al., J. Mol. Biol. 215, 403 to 410 (1990)). The BLASTX program is publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul and others, NCB / NLM / NIH Bethesda, Md. 20894; Altschul and others, above). The well-known Smith Waterman algorithm can also be used to determine identity.
[00066] For example, using the GAP computer algorithm (Genetics Computer Group, University of Wisconsin, Madison, Wis.), Two polypeptides for which the percent sequence identity will be determined are aligned for optimal matching of their respective amino acids (the "matched cycle", as determined by the algorithm). A gap opening penalty (which is calculated as 3 times the mean diagonal; the "mean diagonal" is the mean of the diagonal of the comparison matrix being used; the "diagonal" is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually {fraction (1/10)} times the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in together with the algorithm. A standard comparison matrix (see Dayhoff et al., Atlas of Protein Sequence and Structure, vol. 5, supp.3 (1978) for the PAM 250 comparison matrix; Henikoff et al., Proc. Natl. Acad. Sci USA 89, 10915 to 10919 (1992) for the BLOSUM 62 comparison matrix) is also used by the algorithm.
[00067] Preferred parameters for a peptide sequence comparison include the following: Algorithm: Needleman et al., J. Mol. Biol. 48, 443 to 453 (1970); Comparison matrix: BLOSUM 62 by Henikoff et al., PNAS USA 89, 10915 to 10919 (1992); Gap penalty: 12, Gap length penalty: 4, Similarity limit: 0.
[00068] The GAP program is useful with the above parameters. The parameters mentioned above are the standard parameters for peptide comparisons (along with "no penalty for terminal gaps") using the algorithm.
[00069] A "conservative amino acid substitution" may involve a substitution of an amino acid residue with another residue such that there is little or no effect on the polarity or charge of the amino acid residue at that position. This is exemplified by the following groups of amino acids, where substitutions of an amino acid with a different amino acid in the same group are considered conservative substitutions: Hydrophilic: Ala, Pro, Gly, Glu, Asp, Gin, Asn, Ser, Thr. Aliphatics: Vai, He, Leu, Met. Basic: Lys, Arg, His. Aromatics: Phe, Tyr, Trp. In addition, any residue can often be replaced with alanine.
[00070] Furthermore, if desired, unnatural amino acids or chemical amino acid analogs can be introduced as a substitution or addition to the antibody and / or immunoglobulin chain of the present invention. Such amino acids include, but are not limited to, D-isomers of common amino acids, 2,4-diaminobutyric acid, a-amino isobutyric acid, 4-aminobutyric acid, 2-aminobutyric acid, 6-amino hexanoic acid, 2-amino isobutyric acid , 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citralin, homocitrulline, cystic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, beta-alanine, fluoro-amino acids, such as designer amino acids such as beta-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general.
[00071] The amino acid sequence mutants of the antibody and / or immunoglobulin chain of the present invention can be prepared by introducing appropriate nucleotide changes in a nucleic acid of the present invention, or by in vitro synthesis of the desired polypeptide. Such mutants include, for example, deletions, insertions, or substitutions of residues within the amino acid sequence. A combination of deletion, insertion and substitution can be made to arrive at the final construction, since the final polypeptide product has the desired characteristics. Mutant (altered) polypeptides can be prepared using any technique known in the art. For example, a polynucleotide of the invention can undergo mutagenesis in vitro. Such in vitro mutagenesis techniques include subcloning the polynucleotide into a suitable vector, turning the vector into a "mutant" chain such as E. coli "XL-1 red" (Stratagene) and propagating the transformed bacterium for an appropriate number of generations . Products derived from mutated / altered DNA can be readily screened using techniques described here to determine whether they have receptor binding and / or receptor inhibitory activity.
[00072] When designing amino acid sequence mutants, the location of the mutation site and the nature of the mutation will depend on the characteristics to be modified. The mutation sites can be modified individually or in series, for example, (1) by first replacing with conservative amino acid choices and then with more radical selections depending on the results achieved, (2) deleting the target residue, or ( 3) inserting other residues adjacent to the localized site.
[00073] Amino acid sequence deletions are generally in the range of approximately 1 to 15 residues, more preferably approximately 1 to 10 residues and typically approximately 1 to 5 contiguous residues. description
[00074] The inventors have identified several aspects of relevance to the functionality and effectiveness of biological therapies and particular antibodies, and the main area of the present invention is antibodies for the treatment of inflammatory diseases by inhibiting the binding of C5a to C5aR.
[00075] One aspect of the invention relates to one or more series of antibodies that are characterized by their functionality and / or CDR amino acid sequence, the variable region of heavy and light chains and / or the sequence of the Fc domain.
[00076] In one embodiment, the antibody is a full-length antibody including standard antibody domains and regions.
[00077] In one embodiment, the antibody is an antibody fragment, such fragments can be obtained using conventional or recombinant protein engineering techniques. The antibody fragments of the invention can be made by truncation, for example, by removing one or more amino acids from the N- and / or C-terminal ends of a polypeptide. The fragments can also be generated by one or more internal deletions. An antibody of the invention can be, or can comprise, a fragment of any of the antibodies on which this invention is based. An antibody of the invention may be, or may comprise, an antigen-binding portion of one of these antibodies, or variants thereof. For example, the antibody of the invention may be a Fab fragment of one of these antibodies or variations thereof, or it may be a single chain antibody derived from one of these antibodies, or a variant thereof.
[00078] The antibodies of the invention can be of different species including mammalian species, such as mouse, rat, rabbit, pig, or non-human primate. The antibody can be a rodent antibody and more particularly a mouse antibody. Alternatively, the antibody can be of a non-mammalian species such as chicken. The antibody can further be a humanized antibody or human antibody.
[00079] An antibody of the invention may have the ability to compete with another antibody of the invention for binding to C5aR, as described herein. Such cross-competition antibodies can be identified based on their ability to compete with a known antibody of the invention in standard binding assays. Such cross-competition may suggest that the two antibodies bind to similar, identical or overlapping epitopes. Human Antibodies
[00080] As described in the examples, the inventors identified a series of anti-C5aR antibodies derived from transgenic mice including human immunoglobulin germline loci. The antibodies are isolated as monoclonal hybridoma antibodies and the binding characteristics evaluated. As mentioned, C5aR is one of seven receptors coupled to transmembrane G protein (GPCR) and a soluble form that retains the native conformation is not possible to produce. In order to raise the human antibodies that block the binding of hC5a to hC5aR, transgenic mice were immunized with cells expressing native hC5aR. However, blocking antibodies were very difficult to obtain and 32 fusions were performed by the inventors before a human antibody having the desired blocking properties was identified. From 35 screening fusions of more than 100,000 hybridoma supernatants, a total of 11 blocking antibodies were obtained.
[00081] Furthermore, due to the nature of hC5aR, it was not possible to determine the affinity of the antibodies by standard Biacore analysis, and then the assays were established based on the functional hC5aR-dependent readings, from which the IC50 and EC50 values were determined as described in Example 2 and Example 7.
[00082] In one aspect, the invention relates to a C5aR binding to the human antibody and it is further preferred that the antibody binds to hC5aR specifically, so that the binding to hC5aR is stronger than the binding to C5aR of other species, such as in particular, mouse C5aR. In one embodiment, it is preferred that the antibody bind to the 2nd C5aR extracellular loop and more preferably to the 2nd human C5aR loop. In one embodiment, the antibody binds to the 2nd human C5aR extracellular loop, but not to the 2nd rat C5aR extracellular loop. In additional embodiments, the antibody according to the invention can bind to the 2nd extracellular loop of C5aR in the native conformation only.
[00083] The functionality of an anti-C5aR antibody is dependent on the ability of said antibody to significantly inhibit or reduce the binding of C5a to C5aR.
[00084] In one embodiment, the invention relates to a human antibody binding to C5aR or an antibody, as described here, by definition of sequence (see below) where said antibody is capable of inhibiting or significantly reducing binding from C5a to C5aR. This can be determined by a displacement test (SPA) as described in Example 2 here, from which the IC 50 values can be determined. As is clear from Table 1, the 11 antibodies isolated and described have an IC 50 concentration below 50 nM. In a further embodiment of the invention, the antibody is capable of displacing hC5a in a SPA assay, with an IC 50 below 50 nM, such as below 40 nM, such as below 30 nM, below 20 nM, below 10 nM , below 5 nM or even below 4 nM, or with an IC50 below 3 nM or even below 2.5 nM or 2.0 nM.
[00085] In additional assays, the ability of anti-C5aR antibodies to inhibit C5a-dependent migration of human neutrophils was assessed and some of the identified human antibodies proved to be more potent inhibitors of C5a-mediated neutrophil migration than an anti-C5a antibody. -C5aR previously described (Q from WO 2009/103113). In one embodiment, the invention thus relates to an antibody as described here by definition of a sequence (see below) or a human C5aR binding antibody, where said antibody is capable of significantly inhibiting the migration of human neutrophils. In one embodiment, the antibody inhibits migration to less than 50%, less than 40%, less than 30%, less than 20%, or less than 10% compared to the level of migration observed in the presence of 10 nM of C5a and without anti-C5aR antibody. In such an embodiment, migration is measured after 30 minutes in the presence of 10 nM C5a and antibody compared to the level of migration observed after 30 minutes in the presence of 10 nM C5a and without antibody. Alternatively, the ability of the antibody to inhibit neutrophil migration can be expressed using IC 50 values based on the same configuration. In such an embodiment, the IC50 is below 2.5 pg / ml, as below 2.5 pg / ml, as below 1.5 pg / ml, below 1.2 pg / ml or even below 1.0 pg / ml.
[00086] As an alternative to the standard Biacore analysis, the functionality of hC5aR antibodies can be determined by a competition binding assay on neutrophils, as described in Example 7. This functionality is called antibody affinity, measured by binding to the calling by competition, but could be considered a measurement of interaction activity. The invention in one embodiment relates to an antibody, as described here, by definition of sequence (see below) or a human antibody binding C5aR, where the affinity or avidity of the antibody, measured by competition binding ligand assay in neutrophils, is below 0.80 nM, 0.70 nM, 0.60 nM, such as below 0.50 nM, 0.45 nM, 0.40 nM or 0.35 nM.
[00087] An additional option to characterize the antibodies was explored using a calcium flow assay, which measures an antibody's ability to inhibit C5a-induced neutrophil activation ex vivo, also described in Example 7. In an additional embodiment, the invention relates to an antibody, as described here, by definition of sequence (see below) or a human antibody binding to C5aR, where the IC50, as determined in a calcium flow assay, is below 7, 0 pg / ml, such as below 5.0 pg / ml, such as below 2.5 pg / ml.
[00088] Additional ex vivo assays can be used to determine an antibody's ability to inhibit or neutralize C5a-induced neutrophil maturation based on side effects such as CD11 b and CD62L expression. CD11 b and CD62L are markers of neutrophil maturation, as they are induced or repressed, respectively, through activation by C5a / C5aR interaction.
[00089] The effect on a CD11b induction assay has been determined. In one embodiment, the invention relates to an antibody, as described by sequence definition (see below) or a human antibody binding to C5aR, where the IC50, as determined in the CD11b induction assay is below 3, 5 pg / ml, such as 3.0 pg / ml, below 2.5 pg / ml, below 2.0 pg / ml or such as 1.5 pg / ml or even below 1.0 pg / ml .
[00090] Likewise, the effect of the antibody in a CD62L suppression assay was determined. In one embodiment, the invention relates to an antibody, as described here by definition of sequence (see below) or a human antibody binding to C5aR, where the IC50, as determined in a CD62L repression assay is below 1.8 pg / ml, below 1.5 pg / ml, as below 1.2 pg / ml, or even below 1.0 pg / ml.
[00091] Four monoclonal antibodies were selected by sequencing to determine the sequence of the variable regions and in particular CDR sequences. A sequence alignment is present in figure 1 and the sequences are also included in the attached sequence listing.
[00092] The sequence listing includes the following sequences related to isolated antibodies: SEQ ID 1-3: Vh 35F32A3 CDR 1-3 SEQ ID 4: Vh 35F32A3 SEQ ID 5-7: VI 35F32A3 CDR 1-3 SEQ ID 8: VI 35F32A3 Similarly, SEQ ID 9-16 describes 32F3A6 Similarly, SEQ ID 17-24 describes 35F12A2 Similarly, SEQ ID 25-32 describes 35F24A3 Antibodies defined by variable regions or CDR sequences
[00093] An antibody according to the invention can thus be defined based on the CDR sequences, the sequences of the variable regions of the heavy and light chains and minor modifications that can be performed by those skilled in the art without changing the functionality of the antibody. This includes amino acid substitutions, deletions or insertions of one or more, such as one, two or three amino acid residues within each of the CDR sequences.
[00094] In one aspect, the invention relates to an antibody that binds to C5aR defined by the sequence of the CDR regions, where the variable region of the heavy chain of said antibody comprises CDR1, CDR2, and CDR3 sequences selected from the following groups: a) SEQ ID N °. 1, 2, and 3, where none, one, two or three of said sequences comprise 1, 2 or 3 amino acid (s) replaced (s) with a different amino acid residue; and b) SEQ ID NO. 9, 10, and 11, where none, one, two or three of said sequences comprise 1, 2 or 3 amino acid (s) replaced with a different amino acid residue; and c) SEQ ID NO. 17, 18, and 19, where none, one, two or three of said sequences comprise 1, 2 or 3 amino acid (s) substituted (s) with a different amino acid residue; and d) SEQ ID NO. 25, 26 and 27, where none, one, two or three of said sequences comprise 1, 2 or 3 amino acid (s) replaced with a different amino acid residue.
[00095] In one embodiment, the invention relates to an antibody that binds to C5aR, defined by the sequence of the CDR regions, where the variable region of the heavy chain of said antibody comprises the sequences of CDR1, CDR2 and CDR3; wherein said CDR1 sequence comprises SEQ ID NO. 1, 9,17, 25 or one of said sequences where 1,2 or 3 amino acid (s) are replaced with a different amino acid residue; and where said CDR2 sequence comprises SEQ ID NO. 2, 10, 18, 26 or one of said sequences where 1, 2 or 3 amino acid (s) are replaced with a different amino acid residue; and where said CDR3 sequence comprises SEQ ID NO. 3, 11, 19, 27 or one of said sequences where 1, 2 or 3 amino acid (s) are replaced with a different amino acid residue.
[00096] In one embodiment, the invention relates to an antibody that binds to C5aR defined by the sequence of the CDR regions, where the variable region of the light chain of said antibody comprises sequences of CDR1, CDR2 and CDR3 selected from the following groups: a) SEQ ID NO. 5, 6 and 7, where none, one, two or three of said sequences comprise 1, 2 or 3 amino acid (s) replaced (s) with a different amino acid residue; and b) SEQ ID NO. 13, 14 and 15, where none, one, two or three of said sequences comprise 1, 2 or 3 amino acid (s) replaced with a different amino acid residue; and c) SEQ ID NO. 21,22 and 23, where none, one, two or three of said sequences comprise 1, 2 or 3 amino acid (s) substituted (s) with a different amino acid residue; and d) SEQ ID NO. 29, 30 and 31, where none, one, two or three of said sequences comprise 1, 2 or 3 amino acid (s) replaced with a different amino acid residue.
[00097] In one aspect, the invention relates to an antibody that binds to C5aR, defined by the sequence of the CDR regions, where the variable region of the light chain of said antibody comprises sequences of CDR1, CDR2, and CDR3; wherein said CDR1 sequence comprises SEQ ID NO. 5, 13, 21, 29 or one of said sequences where 1, 2 or 3 amino acid (s) are replaced with a different amino acid residue; and where said CDR2 sequence comprises SEQ ID NO. 6, 14, 22, 30 or one of said sequences where 1, 2 or 3 amino acid (s) are replaced with a different amino acid residue; and where said CDR3 sequence comprises SEQ ID NO. 7, 15, 23, 31 or one of said sequences where 1, 2 or 3 amino acid (s) are replaced with a different amino acid residue.
[00098] In one embodiment, the invention relates to an antibody where the CDRs of the variable region of the heavy chain comprise SEQ ID NO. 1,2 and 3 or said sequence with 1,2 or 3 substitutions, deletions and / or insertions of amino acids and where the CDRs of the variable light chain comprise SEQ ID NO. 5, 6, and 7 or said sequence with 1, 2 or 3 amino acid substitutions, deletions and / or insertions.
[00099] In one embodiment, the invention relates to an antibody where the CDRs of the variable region of the heavy chain comprise SEQ ID NO. 9, 10 and 11 or said sequence with 1, 2 or 3 substitutions, deletions and / or insertions of amino acids and where the CDRs of the variable light chain comprise SEQ ID NO. 13, 14 and 15 or said sequence with 1,2 or 3 substitutions, deletions and / or insertions of amino acids.
[000100] In one embodiment, the invention relates to an antibody where the CDRs of the variable region of the heavy chain comprise SEQ ID NO. 17, 18 and 19 or said sequence with 1, 2 or 3 amino acid substitutions, deletions and / or insertions and where the variable light chain CDRs comprise SEQ ID NO. 21,22 and 23 or said sequence with 1,2 or 3 substitutions, deletions and / or insertions of amino acids.
[000101] In one embodiment, the invention relates to an antibody where the CDRs of the variable region of the heavy chain comprise SEQ ID NO. 25, 26 and 27 or said sequence with 1, 2 or 3 substitutions, deletions and / or insertions of amino acids and where the CDRs of the variable light chain comprise SEQ ID NO. 29, 30 and 31 or said sequence with 1,2 or 3 substitutions, deletions and / or insertions of amino acids.
[000102] One embodiment of the invention thus relates to an antibody, where the variable region of the heavy chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said CDR sequences comprise one of the following groups of sequences; SEQ ID NO. 1, 2 and 3, SEQ ID NO. 9, 10 and 11, SEQ ID NO. 17, 18 and 19, SEQ ID NO. 25, 26 and 27 or said sequences with up to two substitutions, deletions and / or insertions per sequence and where the variable region of the light chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said CDR sequences comprise a of the following groups of sequences; SEQ ID NO. 5, 6 and 7, SEQ ID NO. 13, 14 and 15, SEQ ID NO. 21, 22 and 23, SEQ ID NO. 29, 30 and 31, or said sequences with up to two substitutions, deletions and / or insertions per sequence.
[000103] One embodiment of the invention thus relates to an antibody, where the variable region of the heavy chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, wherein said CDR sequences comprise one of the following groups of sequences; SEQ ID NO. 1.2 and 3, SEQ ID NO. 9, 10 and 11, SEQ ID NO. 17, 18 and 19, SEQ ID NO. 25, 26 and 27 or said sequences with up to one substitution, deletion and / or insertion per sequence and where the variable region of the light chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said CDR sequences comprise a of the following groups of sequences; SEQ ID NO. 5, 6 and 7, SEQ ID NO. 13, 14 and 15, SEQ ID NO. 21, 22 and 23, SEQ ID NO. 29, 30 and 31, or said sequences with up to one substitution, deletion and / or insertion per sequence.
[000104] One embodiment of the invention thus relates to an antibody, where the variable region of the heavy chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, wherein said CDR sequences comprise one of the following groups of sequences; SEQ ID NO. 1.2 and 3, SEQ ID NO. 9, 10 and 11, SEQ ID NO. 17, 18 and 19, SEQ ID NO. 25, 26 and 27 and where the variable region of the light chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, wherein said CDR sequences comprise one of the following groups of sequences; SEQ ID NO. 5, 6 and 7, SEQ ID NO. 13, 14 and 15, SEQ ID NO: 21,22 and 23, SEQ ID NO. 29, 30 and 31.
[000105] One embodiment of the invention relates to an antibody where the variable region of the heavy chain of said antibody comprises a sequence at least 80, 85, 90 or 94% identical to SEQ ID NO. 4, 12, 20 or 28.
[000106] One embodiment of the invention relates to an antibody where the variable region of the heavy chain of said antibody comprises a sequence at least 96, 97, 98 or 99% identical to SEQ ID NO. 4, 12, 20 or 28.
[000107] One aspect of the invention relates to an antibody where the variable region of the light chain of said antibody comprises a sequence at least 80, 85, 90 or 94% identical to SEQ ID NO. 8, 16, 24 or 32.
[000108] One embodiment of the invention relates to an antibody where the variable region of the light chain of said antibody comprises a sequence at least 96, 97, 98 or 99% identical to SEQ ID NO. 8, 16, 24 or 32.
[000109] One embodiment of the invention relates to an antibody where the variable region of the heavy chain of said antibody comprises a sequence at least 80, 85, 90 or 94% identical to SEQ ID NO. 4, 12, 20 or 28 and / or where the variable region of the light chain of said antibody comprises a sequence at least 80, 85, 90 or 94% identical to SEQ ID NO: 8, 16, 24 or 32.
[000110] One embodiment of the invention relates to an antibody where the variable region of the heavy chain of said antibody comprises a sequence at least 96, 97, 98 or 99% identical to SEQ ID NO. 4 and / or where the variable region of the light chain of said antibody comprises a sequence at least 96, 97, 98 or 99% identical to SEQ ID NO. 8.
[000111] One embodiment of the invention relates to an antibody where the variable region of the heavy chain of said antibody comprises a sequence at least 96, 97, 98 or 99% identical to SEQ ID NO. 12 and / or where the variable region of the light chain of said antibody comprises a sequence at least 96, 97, 98 or 99% identical to SEQ ID NO. 16.
[000112] One embodiment of the invention relates to an antibody where the variable region of the heavy chain of said antibody comprises a sequence at least 96, 97, 98 or 99% identical to SEQ ID NO. 20 and / or where the variable region of the light chain of said antibody comprises a sequence at least 96, 97, 98 or 99% identical to SEQ ID NO. 24.
[000113] One embodiment of the invention relates to an antibody where the variable region of the heavy chain of said antibody comprises a sequence at least 96, 97, 98 or 99% identical to SEQ ID NO. 28 and / or where the variable region of the light chain of said antibody comprises a sequence at least 96, 97, 98 or 99% identical to SEQ ID NO. 32.
[000114] One embodiment of the invention relates to an antibody where the variable region of the heavy chain of said antibody comprises a sequence at least 96, 97, 98 or 99% identical to SEQ ID NO. 39 and / or where the variable region of the light chain of said antibody comprises a sequence at least 96, 97, 98 or 99% identical to SEQ ID NO. 40.
[000115] One embodiment of the invention relates to an antibody where the variable region of the heavy chain of said antibody is identified by SEQ ID NO. 39 and / or where the variable region of the light chain of said antibody is identified by SEQ ID NO. 40.
[000116] During the maturation of the antibodies, spontaneous mutations in the structure region can occur, as described here, in Examples 6 and 7, the variable region of one of the isolated monoclonal antibodies was compared for both the variable heavy chain and the light chain variable. In order to minimize the risk of immunological reaction, it was decided to optimize the antibodies by introducing point mutations in the structure region to build an antibody with human germline sequence in the structure regions, as can be seen from the experiments , this did not influence the functionality of the antibody.
[000117] In one embodiment, the invention relates to an antibody defined by sequence identity for a variable region of a reference antibody, as described here above, where the variable region of the heavy chain and / or the light chain of said antibody comprises one or more mutations in the framework region. It may, according to the invention, be attractive to introduce one or more mutations to increase the identity of the closest human germline sequence, although other mutations may also be considered. In one embodiment, such mutations are conservative mutations. Antibodies Defined by Region Fc
[000118] The Fc region enables antibodies to activate the immune system and antibodies are designed to include modifications within the Fc region, typically to alter one or more of its functional properties, such as serum half-life, complement fixation, binding to the Fc receptor, protein stability, and / or antigen-dependent cell cytotoxicity, or lack thereof. In addition, an antibody of the invention can be chemically modified (for example, one or more chemical moieties can be coupled to the antibody) or be modified to alter its glycosylation, again to alter one or more functional properties of the antibody.
[000119] One aspect of the invention relates to a C5aR binding antibody or an antibody as described here by sequence definition (see below), where the Fc region has reduced or abolished binding affinity with one or more FcyRs.
[000120] One aspect of the invention relates to a C5aR-binding antibody or an antibody as described here by sequence definition (see below), where the Fc region has reduced binding affinity with one or more FcyRs.
[000121] In one embodiment, the antibody of the invention exhibits reduced binding affinity with one or more FcyRs compared to the Fc reference sequence of IgG1, IgG2, IgG2 / 4 or IgG4 as defined by SEQ ID NO. 33, 34, 35 and 36, respectively. Since the specific amino acid residues may be responsible for the interaction of FcyRs and the effects mediated here, it may be advantageous to apply an antibody where such specific amino acid residues from the Fc region have been replaced by a different amino acid.
[000122] In one embodiment, said Fc region includes one or more point mutations compared to the IgG 1, IgG2, IgG2 / 4 or IgG4 Fc reference sequences as defined by SEQ ID NO. 33, 34, 35 and 36, respectively, reducing the affinity with one or more Fcy receptors or complementary components.
[000123] In order to evaluate the result of introducing point mutations in the Fc region, the effector functions for a series of anti-C5aR antibodies were evaluated as described in Example 4. A phagocytosis assay was established to measure the function of the Fc region in ability of anti-hC5aR antibodies to induce neutrophil phagocytosis (expressing hC5aR) by human monocytes. As can be seen from Table 2, several Fc variants decrease the level of phagocytosis induced by anti-C5aR antibodies in the described assay.
[000124] In one embodiment, the antibody according to the invention does not significantly induce neutrophil phagocytosis in vitro, meaning that the phagocytosis level is not significantly above the base level, measured in the absence of an anti-C5aR antibody. In one embodiment, the antibody does not give rise to any detectable induction of phagocytosis. The assay to assess the level of phagocytosis can be performed using human neutrophils, as described in Example 4.
[000125] In alternative assays, the ability of anti-hC5aR antibodies to induce ADCC (antibody-dependent cell cytotoxicity) and CDC (complement-dependent cytotoxicity) was assessed. The assays were established to test the ability of the Fc variants to mediate cell depletion via ADCC or CDC-dependent mechanisms, and it is assumed that they are capable of simulating activities in an in vivo configuration.
[000126] The assays apply cells expressing hC5aR as target cells and effector cells (monocyte-depleted PMBCs) or serum containing complement to produce the responses, as described in Example 4.
[000127] In one embodiment, the antibody according to the invention does not significantly induce ADCC, meaning that the ADCC level is not significantly above the base level, measured in the absence of an anti-C5aR antibody. In one embodiment, the antibody does not give rise to any detectable ADCC induction, that is, the ADCC level is not above the base level.
[000128] In one embodiment, the antibody according to the invention does not significantly induce CDC. In one embodiment, the antibody does not give rise to any detectable CDC induction, that is, the CDC level is not above the base level.
[000129] In one embodiment, the antibody according to the invention comprises an Fc region where the sequence has been modified to alter the function or functions of the effector cell. Modification of the Fc sequence can be achieved by point mutations in the amino acid sequence. The heavy chain Fc region can be a chimeric sequence of IgG1, IgG2, IgG4 or IgG2 / 4. Reference strings are defined in the sequence listing as follows; IgG 1 by SEQ ID NO. 33; IgG2 by SEQ ID NO: 34; IgG2 / 4 by SEQ ID No. 35 and IgG4 by SEQ ID No. 36.
[000130] In one embodiment, the Fc region is an IgG 1 (SEQ ID NO: 33), IgG2 (SEQ ID NO: 34), IgG2 / 4 (SEQ ID NO: 35), or IgG4 (SEQ ID N °: 36), with one or more of the following point mutations: a. E233P b. L234A or V234A or F234L or F234V c. L235E or L235A d. G236R or G236A e. G237A f. S239D g. S254W h. N297Q i. L328R j. A330S k. P331S l. I332E
[000131] The difference between the Fc variants lies in their ability to interact with FcyRs or components of the complementary system described above. Sequence differences in the Fc region further affect the structure and flexibility of the antibody, which can also affect the function of the antibody. As described in Example 5 and Table 3, the inventors further demonstrate that anti-hC5aR antibodies, where the Fc region is of the IgG 1 type with or without additional point mutations, are more potent inhibitors of hC5aR-mediated effects than antibodies corresponding to the lgG4 Fc region. Accordingly, one embodiment of the invention relates to any of the antibodies defined herein with an IgG 1 isotype Fc region or at least an IgG 1 isotype Fc hinge region.
[000132] In one embodiment, the lgG1 Fc region comprises 1 to 10 amino acid substitutions compared to the lgG1 Fc reference sequence as defined in SEQ ID NO. 33. It is preferred that the Fc regions comprise fewer mutations, such as 1 to 8 amino acid substitutions within AA 231 to 240, or such as 1 to 5 amino acid substitutions within AA 328 to 334. Amino acid substitutions are selected preferably among substitutions that reduce the ability of the antibody to significantly induce neutrophil phagocytosis, ADCC and / or CDC in vitro as described above.
[000133] In one embodiment, the antibody Fc region is a lgG1 comprising one or more of the following point mutations: a) N297Q and / or b) L234A and / or c) L235E or L235A and / or d) G236R or G236A and / or e) G237A and / or f) L328R and / or g) A330S and / or h) P331S.
[000134] In one embodiment, the Fc region of the antibody is an lgG1 comprising one or more of the following point mutations: a) N297Q and / or b) L234A and L235E and / or c) L234A and G236R and / or d) L235E and G236R and / or e) L234A, L235E and G236R and / or f) G236R and L328R and / or g) N297Q, L234A and L235E and / or h) N297Q, L234A, L235E and G236R and / or i) N297Q, L234A, L235E and G237A and / or j) L234A, L235E, G237A, A330S and P331S. k) N297Q, L234A, L235E, G237A, A330S and P331S.
[000135] In one embodiment, the antibody Fc region is an lgG1 comprising one or more of the following point mutations: a) N297Q and / or b) L234A and L235E and / or c) G236R and L328R and / or d) N297Q, L234A and L235E and / or e) N297Q, L234A, L235E and G237A and / or f) L234A, L235E, G237A, A330S and P331S.
[000136] It is clear to those skilled in the art that point mutations within the framework region of both heavy and light chains that can be introduced based on standard criteria for replacing amino acid residues are within the scope of the invention. Functional assays, as described here, can be used to confirm that such mutations do not influence the functionality of the antibody.
[000137] As is clear, the binding specificity of the identified antibodies is provided by the variable regions or CDRs, and it is clear that different types of antibodies having a similar antigenic binding region are covered by the invention.
[000138] In one embodiment of the invention, the antibody is a full length antibody. In one embodiment of the invention, the antibody is an antibody fragment or a single chain antibody. In one embodiment, the antibody is a monoclonal antibody. In one embodiment, the antibody is a human, mouse, rat, rabbit, pig, or non-human primate antibody. In one embodiment, the antibody is a mouse or human antibody. In one embodiment, the antibody is a human antibody. In one embodiment, the antibody is a humanized antibody. As described in the definition part of the application, a humanized antibody includes at least CDR regions not derived from the human germline sequence. As is clear, a human antibody can comprise one or more point mutations compared to the germline sequence, but it is generally considered that the sequence should at least in the framework region or Fc region be at least 95% identical to the lineage sequences human germinative. Pharmaceutical Formulations
[000139] The present invention further includes pharmaceutical compositions / formulations, comprising a pharmaceutically acceptable carrier and a polypeptide or antibody according to the invention, as well as kits comprising such compositions.
[000140] The antibody according to the invention can, in one aspect of the invention, be formulated in a pharmaceutical composition. Such a pharmaceutical composition can be prepared based on general knowledge in the field such as Pharmacopeia or Remington.
[000141] In one embodiment, the pharmaceutical composition, according to the invention, comprises an antibody, as described herein, in combination with a pharmaceutically acceptable carrier. The formulation can be in the form of an aqueous formulation or a dry formulation that is reconstituted in water or an aqueous buffer composition before administration.
[000142] A pharmaceutical antibody composition according to the invention can comprise a salt and / or buffer, such as the compositions described in WO 2011/104381.
[000143] In an additional embodiment, the pharmaceutical composition of antibodies according to the invention can be suitable for multiple users, such as the compositions described in WO 2011/147921. Treatment Method
[000144] One aspect of the invention relates to a method for treating or preventing a disorder in an individual, the method comprising administering to an individual in need of treatment, a therapeutic amount of an antibody as described herein. As described in previous publications, such as WO 2009/103113, anti-C5aR antibodies are used / suitable for the treatment of various diseases and disorders. One embodiment of the invention thus relates to a method for treating an immune disease or disorder, in particular an inflammatory disease. Example 8 provided here further supports this by demonstrating the functionality of an anti-C5aR antibody according to the invention in a mouse arthritis model. Examples 9 to 11 demonstrate the inhibition of C5aR in tissue samples from patients with psoriatic arthritis, Crohn's disease and ulcerative colitis. It is also shown that an anti-C5aR antibody can inhibit the synovial fluid-induced migration of PMNs from patients with psoriatic arthritis.
[000145] A treatment method may aim to cure a disease or disorder, but in relation to some diseases, including immune and inflammatory diseases, such as chronic diseases or disorders, the relief of one or more symptoms is also considered a treatment, which can be a significant improvement for the individual, even if only partial relief of symptoms is obtained or the effect is temporary or partial.
[000146] The method according to the invention includes treatment of one or more diseases including, but not limited to rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, systemic lupus erythematosus (SLE), lupus nephritis, type I diabetes, Severe, inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (CU), irritable bowel syndrome, multiple sclerosis (MS), autoimmune myocarditis, Kawasaki disease, coronary artery disease, chronic obstructive pulmonary disease ( COPD), interstitial lung disease, autoimmune thyroiditis, scleroderma, systemic sclerosis, osteoarthritis, atopic dermatitis, vitiligo, graft versus host disease, Sjogren's syndrome, autoimmune nephritis, Goodpasture's syndrome, chronic inflammatory demyelinating polyneuropathy, ANCA-associated vasculitis, uveitis bullous pemphigoid, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's chorea, cystic fibrosis, gout, age-related macular degeneration, allergy, asthma, and other autoimmune diseases that are a result of either acute or chronic inflammation, where the disorder may be an autoimmune disease. In one embodiment, the disorder is rheumatoid arthritis (RA), psoriatic arthritis, systemic lupus erythematosus (SLE), lupus nephritis, inflammatory bowel disease (Dll), Crohn's disease (CD), ulcerative colitis (CU) or irritable bowel syndrome . In additional modalities, the disorder is AR or SLE. Apart from chronic diseases, anti-C5aR antibodies may be relevant in relation to acute indications such as transplantation, ischemia / reperfusion injury (eg, acute myocardial infarction, stroke), sepsis (eg, SIRS, MODS, ALI ), atherosclerosis, and intracerebral hemorrhage (ICH).
[000147] In a further aspect, the invention relates to an antibody, an isolated antibody or antibody composition, as described herein, for the treatment of a disease or disorder. In additional embodiments, said antibody, isolated antibody or antibody composition is for the treatment of one or more of the diseases and disorders described herein above in relation to a treatment method.
[000148] One aspect of the invention relates to the use of an antibody, an isolated antibody or antibody composition as described herein, for the preparation of a medicament for the treatment of a disease or disorder, where the disease or disorder can be as described above in relation to a treatment method. Administration Mode
[000149] An antibody of the invention can be administered parenterally, such as intravenously, intramuscularly, or subcutaneously. Alternatively, an antibody of the invention can be administered via a non-parenteral route, such as orally or topically. An antibody of the invention can be administered prophylactically. In a preferred embodiment, the antibody is administered intravenously or subcutaneously.
[000150] The dosage and time of administration will most likely depend on several factors including the disease / disorder or symptoms, as well as the individual in question. In general, the antibody is expected to be administered in doses of 0.010 mg / kg up to 4 to 6 mg / kg. Likewise, the dosage regimen of the antibody will also depend on the individual subject and the disease state of said individual, but it is desirable according to the invention to employ a treatment where the antibody (or antibody composition) is administered to the individual once a week. or every two weeks or even at smaller intervals, such as once a month.
[000151] An antibody of the invention can be administered on demand, that is, the antibody can be administered based on the experience of the patients, for example, when particular symptoms arrive or when the quantity of particular biomarkers reaches a predefined level. Specific Combination Treatments
[000152] The antibodies of the invention can be co-administered with one or more other therapeutic agents or formulations. The other agent can be an agent that enhances the effects of the antibodies of the invention. The other agent may be designed to treat the patient's other symptoms or conditions. For example, the other agent can be an analgesic, an immunosuppressant, or an anti-inflammatory agent. The other agent can be another monoclonal antibody, such as those described in international patent applications WO 2008/022390 and WO 2009/103113.
[000153] The combined administration of two or more agents can be achieved in several ways. In one embodiment, the antibody and the other agent can be administered together in a single composition. In another embodiment, the antibody and the other agent can be administered in separate compositions as part of a combination therapy. For example, the modulator can be administered before, after, or simultaneously with the other agent.
[000154] The antibodies according to the present invention can be administered together with other drugs (for example, methotrexate, dexamethasone, and prednisone) and / or other biological drugs. In one embodiment, according to the invention, an antibody may be co-administered with one or more therapeutic agents selected from the ATC code M01C class of antirheumatic drugs and ATC code L04 of immunosuppressants as described in WO 2009/103113 including, but not limited to azathioprine, chloroquine, hydroxychloroquine, cyclosporine, D-penicillamine, gold salts (sodium aurothiomalate, auranofm), leflunomide, methotrexate, minocycline, sulfasalazine, cyclophosphamide, glucocorticoid, mycophenolate and mycophenolate, and mycophenolate and mycophenol, one or more among Plaquenil, Azulfidina, and Methotrexato, dexametasona and / or prednisone.
[000155] In another example, the antibodies of the present invention can also be used in combination with other antibodies (for example, in combination with antibodies that bind to chemokine receptors, including, but not limited to CCR2 and CCR3) or with agents anti-TNF and other anti-inflammatory agents or with existing blood plasma products, such as commercially available gamma globulin and immune globulin products used in prophylactic or therapeutic treatments. The antibodies of the present invention can be used as compositions administered separately in conjunction with antibiotic and / or antimicrobial agents.
[000156] Antibodies can be administered in combination with agents such as agents already in use in autoimmunity including, but not limited to immune modulators, such as IFN-beta, Orencia ™ (CTLA4-lg), Humira ™ (anti-TNF) , Cimzia ™ (anti-TNF, PEG Fab), Tysabri ™ (a4-integrin mAb), Simponi ™, Rituxan / MabThera ™, Actemra / RoActemra ™, Kineret ™, Raptiva, Ustekimumab, non-steroidal anti-inflammatory drugs (NSAIDS) like Asprina ™, Ibuprofen ™ etc., Corticosteroids, disease-modifying antirheumatic drugs (DMARDS) like Plaquenil ™, Azulfidina ™, Methotrexate ™, etc., Copaxone ™ (glatiramer acetate), Gilneya ™ (fingolimod), antibiotics like Flagyl ™ , Cipro ™, Topical medications (applied to the skin) including topical corticosteroids, vitamin D analog creams (Dovonex ™), topical retinoids (Tazorac ™), humidifiers, topical immunomodulators (tacrolimus and pimecrolimus), mineral tar, anthralin, and others, and additionally also PUVA, UVB and CelICept ™ light therapy (mico mofetil phenolate) can be combined with the treatment using the antibodies according to the invention.
[000157] It may be that the individual to be treated is already being treated with one or more other drugs in the event that the antibody of the invention can be added to said treatment regimen. Method for Antibody Preparation
[000158] An antibody can be prepared by several methods known in the art mainly with or with hybridoma clones for the production of the antibody or the expression of the antibody in a recombinant host, if the latter is described in WO 2010/000864. Based on knowledge in the art, a nucleotide sequence encoding a desired antibody chain can be constructed and used for recombinant expression of an antibody where the light and heavy chains can be expressed from one or two separate polynucleotides.
[000159] The present invention in a further aspect relates to one or more isolated polynucleotides encoding a polypeptide sequence of an antibody chain of an antibody described herein.
[000160] An additional embodiment relates to a host cell comprising one or more polynucleotides encoding a polypeptide sequence (s) of an antibody chain of an antibody described herein.
[000161] The invention further relates to a process for producing an antibody according to the invention, comprising culturing a host cell described above under conditions that support the expression of one or more polypeptide sequence (s) from an antibody chain . The process may further include that the antibody chains are encoded by two separate open reading frames in a contiguous polynucleotide and optionally that the antibody is recovered from said host cell culture.
[000162] The present invention can, without being limited to these, be described by the following modalities. Modalities 1. An antibody where the variable region of the heavy chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said sequence of CDR1 comprises SEQ ID NO. 1 or said sequence with 1,2 or 3 amino acid substitutions, deletions, or insertions and / or where said CDR2 sequence comprises SEQ ID NO. 2 or said sequence with 1,2 or 3 amino acid substitutions, deletions, or insertions and / or where said CDR3 sequence comprises SEQ ID NO. 3 or said sequence with 1, 2 or 3 substitutions, deletions, or insertions of amino acids. 2. An antibody, where the variable region of the heavy chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said CDR sequences comprise SEQ ID NO. 1,2 and 3 or variants of said sequences where 1, 2 or 3 amino acids are replaced by a different amino acid residue. 3. An antibody, where the variable region of the heavy chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said CDR sequences are identical to SEQ ID NO. 1.2 and 3. 4. An antibody, where the variable region of the light chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said sequence of CDR1 comprises SEQ ID NO. 5 or said sequence with 1,2 or 3 substitutions, deletions, or insertions of amino acids and / or where said sequence of CDR2 comprises SEQ ID NO. 6 or said sequence with 1,2 or 3 substitutions, deletions, or insertions of amino acids and / or where said sequence of CDR3 comprises SEQ ID NO. 7 or said sequence with 1, 2 or 3 substitutions, deletions, or insertions of amino acids. 5. An antibody, where the variable region of the light chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, wherein said CDR sequences comprise SEQ ID NO. 5, 6 and 7 or variants of said sequences where 1, 2 or 3 amino acids are replaced by a different amino acid residue. 6. An antibody, where the variable region of the light chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said CDR sequences are identical to SEQ ID NO. 5, 6 and 7. 7. An antibody, where the variable region of the heavy chain is defined as in any of modalities 1, 2 or 3, and where the variable region of the light chain is defined as in any of modalities 4, 5 or 6. 8. An antibody where the variable region of the heavy chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said sequence of CDR1 comprises SEQ ID NO. 9 or said sequence with 1,2 or 3 substitutions, deletions, or insertions of amino acids and / or where said sequence of CDR2 comprises SEQ ID NO. 10 or said sequence with 1,2 or 3 substitutions, deletions, or insertions of amino acids and / or where said sequence of CDR3 comprises SEQ ID NO. 11 or said sequence with 1,2 or 3 substitutions, deletions, or insertions of amino acids. 9. An antibody, where the variable region of the heavy chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, wherein said CDR sequences comprise SEQ ID NO. 9, 10 and 11 or variants of said sequences where 1, 2 or 3 amino acids are replaced by a different amino acid residue. 10. An antibody, where the variable region of the heavy chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said CDR sequences are identical to SEQ ID NO. 9, 10 and 11. 11. An antibody, where the variable region of the light chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said sequence of CDR1 comprises SEQ ID NO. 13 or said sequence with 1,2 or 3 substitutions, deletions, or insertions of amino acids and / or where said sequence of CDR2 comprises SEQ ID NO. 14 or said sequence with 1,2 or 3 amino acid substitutions, deletions, or insertions and / or where said CDR3 sequence comprises SEQ ID NO. 15 or said sequence with 1,2 or 3 substitutions, deletions, or insertions of amino acids. 12. An antibody, where the light chain variable region of said antibody comprises a sequence of CDR1, CDR2 and CDR3, wherein said CDR sequences comprise SEQ ID NO. 13, 14 and 15 or variants of said sequences where 1, 2 or 3 amino acids are replaced by a different amino acid residue. 13. An antibody, where the variable region of the light chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said CDR sequences are identical to SEQ ID NO. 13, 14 and 15. 14. An antibody, where the variable region of the heavy chain is defined as in any of the modalities 8, 9 and 10, and where the variable region of the light chain is defined as in any of the modalities 11, 12 or 13. 15. An antibody where the variable region of the heavy chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said sequence of CDR1 comprises SEQ ID NO. 17 or said sequence with 1,2 or 3 substitutions, deletions, or insertions of amino acids and / or where said sequence of CDR2 comprises SEQ ID NO. 18 or said sequence with 1,2 or 3 substitutions, deletions, or insertions of amino acids and / or where said sequence of CDR3 comprises SEQ ID NO. 19 or said sequence with 1,2 or 3 substitutions, deletions, or insertions of amino acids. 16. An antibody, where the variable region of the heavy chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, wherein said CDR sequences comprise SEQ ID NO. 17, 18 and 19 or variants of said sequences where 1, 2 or 3 amino acids are replaced by a different amino acid residue. 17. An antibody, where the variable region of the heavy chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said CDR sequences are identical to SEQ ID NO. 17, 18 and 19. 18. Antibody, where the variable region of the light chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said sequence of CDR1 comprises SEQ ID NO. 21 or said sequence with 1,2 or 3 substitutions, deletions, or insertions of amino acids and / or where said sequence of CDR2 comprises SEQ ID NO. 22 or said sequence with 1,2 or 3 amino acid substitutions, deletions, or insertions and / or where said CDR3 sequence comprises SEQ ID NO. 23 or said sequence with 1,2 or 3 substitutions, deletions, or insertions of amino acids. 19. An antibody, where the variable region of the light chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, wherein said CDR sequences comprise SEQ ID NO. 21, 22 and 23 or variants of said sequences where 1, 2 or 3 amino acids are replaced by a different amino acid residue. 20. An antibody, where the variable region of the light chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said CDR sequences are identical to SEQ ID NO. 21, 22 and 23. 21. An antibody, where the variable region of the heavy chain is defined as in any of the modalities 15,16 or 17, and where the variable region of the light chain is defined as in any of the modalities 18, 19 or 20. 22. An antibody where the variable region of the heavy chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said sequence of CDR1 comprises SEQ ID NO. 25 or said sequence with 1,2 or 3 substitutions, deletions, or insertions of amino acids and / or where said sequence of CDR2 comprises SEQ ID NO. 26 or said sequence with 1,2 or 3 amino acid substitutions, deletions, or insertions and / or where said CDR3 sequence comprises SEQ ID NO. 27 or said sequence with 1,2 or 3 substitutions, deletions, or insertions of amino acids. 23. An antibody, where the variable region of the heavy chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, wherein said CDR sequences comprise SEQ ID NO. 25, 26 and 27 or variants of said sequences where 1, 2 or 3 amino acids are replaced by a different amino acid residue. 24. An antibody, where the heavy chain variable region of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said CDR sequences are identical to SEQ ID NO. 25, 26 and 27. 25. An antibody, where the variable region of the light chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said sequence of CDR1 comprises SEQ ID NO. 29 or said sequence with 1,2 or 3 substitutions, deletions, or insertions of amino acids and / or where said sequence of CDR2 comprises SEQ ID NO. 30 or said sequence with 1,2 or 3 substitutions, deletions, or insertions of amino acids and / or where said sequence of CDR3 comprises SEQ ID NO. 31 or said sequence with 1,2 or 3 substitutions, deletions, or insertions of amino acids. 26. An antibody, where the variable region of the light chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, wherein said CDR sequences comprise SEQ ID NO. 29, 30 and 31 or variants of said sequences where 1, 2 or 3 amino acids are replaced by a different amino acid residue. 27. An antibody, where the variable region of the light chain of said antibody comprises a sequence of CDR1, CDR2 and CDR3, where said CDR sequences are identical to SEQ ID NO. 29, 30, 31. 28. An antibody, where the variable region of the heavy chain is defined as in any of the modalities 22,23 or 24, and where the variable region of the light chain is defined as in any of the modalities 25, 26 or 27. 29. An antibody, where the variable region of the heavy chain of said antibody comprises a sequence at least 80, 85, 90 or 94% identical to SEQ ID NO. 4, 12, 20 or 28. 30. The antibody, according to embodiment 29, where the variable region of the heavy chain of said antibody comprises one or more mutations in the structure region. 31. The antibody, according to modality 29, where said mutations are conservative mutations. 32. The antibody, according to modality 29, where said mutations increase the identity with the closest human germline sequence. 33. The antibody, according to modality 32, where the variable region of the heavy chain of said antibody is identified by SEQ ID NO. 39. 34. An antibody, where the variable region of the light chain of said antibody comprises a sequence at least 80, 85, 90 or 94% identical to SEQ ID NO. 8, 16, 24 or 32. 35. The antibody, according to modality 34, where the variable region of the light chain of said antibody comprises one or more mutations in the structure region. 36. The antibody, according to modality 35, where said mutations are conservative mutations. 37. The antibody, according to modality 35, where said mutations increase the identity with the closest human germline sequence. 38. The antibody, according to modality 34, where the variable region of the light chain of said antibody is identified by SEQ ID NO. 40. 39. An antibody, where the variable region of the heavy chain of said antibody comprises a sequence at least 80, 85, 90 or 94% identical to SEQ ID NO. 4, 12, 20 or 28 and where the variable region of the light chain of said antibody comprises a sequence at least 80, 85, 90 or 94% identical to SEQ ID NO. 8, 16, 24 or 32. 40. The antibody, according to modality 39, where the sequence of said heavy chain variable regions has at least 96%, such as 97%, 98%, or 99% identity with SEQ ID NO. 4, 12, 20 or 28 and where the sequence of said light chain variable region has at least 96%, such as 97%, 98%, or 99% identity with SEQ ID NO. 8, 16, 24 or 32. 41. The antibody, according to modality 39 or 40, where the variable region of the heavy chain of said antibody comprises one or more mutations in the structure region and / or where the variable region of the chain The light weight of said antibody comprises one or more mutations in the framework region. 42. The antibody, according to modality 41, where said mutations are conservative mutations. 43. The antibody, according to modality 41, where said mutations increase the identity with the closest human germline sequence. 44. The antibody, according to modality 41, where the variable region of the heavy chain of said antibody is identified by SEQ ID NO. 39 and / or where the variable region of the light chain of said antibody is identified by SEQ ID NO. 40. 45. The antibody, according to any of the above embodiments, where said antibody binds to C5aR. 46. The antibody, according to any of the foregoing embodiments, wherein said antibody is a full-length antibody or an antibody fragment or a single chain antibody. 47. The antibody, according to any of the above embodiments, wherein said antibody is a monoclonal antibody. 48. The antibody, according to any of the above embodiments, wherein said antibody is a human, mouse, rat, rabbit, pig or non-human primate antibody. 49. The antibody, according to any of the foregoing modalities, wherein said antibody is a mouse or human antibody. 50. The antibody, according to any of the above embodiments, wherein said antibody is a human antibody or a humanized antibody. 51. The antibody, according to any of the foregoing embodiments, wherein said antibody is a human antibody. 52. A human antibody that binds to C5aR. 53. The antibody, according to any of the above embodiments, where said antibody binds to human C5aR. 54. The antibody, according to any of the previous modalities, where said antibody binds to the 2nd extracellular loop of C5aR. 55. The antibody, according to any of the foregoing modalities, where said antibody binds to the 2nd human C5aR extracellular loop. 56. The antibody, according to any of the above embodiments, wherein said antibody binds to human C5aR, but not to rat C5aR. 57. The antibody, according to any of the previous modalities, where said antibody binds to the 2nd extracellular loop of human C5aR, but not to the 2nd extracellular loop of C5aR of rats. 58. The antibody, according to any of the previous modalities, where said antibody binds to the 2nd extracellular loop of human C5aR in the native conformation only. 59. The antibody, according to any of the foregoing embodiments, wherein said antibody significantly inhibits or re-bonds the binding of C5a to human C5aR. 60. The antibody, according to any of the previous modalities, where said antibody is capable of removing C5a in a SPA assay, with an IC50 below 10 nM or below 5 nM or preferably below 3 nM. 61. The antibody, according to any of the previous modalities, where said antibody significantly inhibits the migration of human neutrophils in vitro. 62. The antibody, according to any of the previous modalities, where said antibody reduces migration to less than 50%, less than 40%, less than 30%, less than 20%, less than 15%, or less than 10%, when measured after 30 minutes in the presence of 10 nM C5a compared to the migration level observed after 30 minutes in the presence of 10 nM C5a and without antibody or where the IC50 in the same configuration is below 2.5 pg / ml , such as below 1.5 pg / ml, below 1.2 pg / ml, or even below 1.0 pg / ml. 63. The antibody, according to any of the previous modalities, where the affinity of the antibody, measured by neutrophil ligand binding competition assay, is below 0.80 nM, such as below 0.50 nM or 0 , 35 nM. 64. The antibody, according to any of the previous modalities, where said antibody neutralizes C5a-induced neutrophil ex vivo activation with an IC50 as determined in a calcium flow assay below 7.0 pg / ml, below 5.0 pg / ml, below 2.5 pg / ml. 65. The antibody, according to any of the foregoing modalities, wherein said antibody inhibits C5a-induced neutrophil maturation ex vivo with a. an IC50, as determined in a CD11b induction assay, below 3.5 pg / ml, such as below 2.5 pg / ml, such as below 1.5 pg / ml or even below 1.0 pg / ml, or b. An IC50, as determined in a CD62L suppression assay, below 1.8 pg / ml, below 1.5 pg / ml, as below 1.2 pg / ml, or even below 1.0 pg / ml ml. 66. A C5aR binding antibody, where the Fc region has reduced affinity / binding to one or more Fcy receptors compared to Fc reference sequences lgG1, lgG2, lgG4 or lgG4 / G2, as defined by SEQ ID NO. 33, 34, 35 and 36, respectively. 67. The antibody, according to any of the previous modalities, where the Fc region includes one or more point mutations compared to the reference sequences of Fc IgG1, IgG2, IgG4 or IgG4 / G2, as defined by SEQ ID NO. 33, 34, 35 and 36, respectively, reducing affinity to one or more Fey receptors. 68. The antibody, according to any of the previous modalities, where the antibody does not significantly induce neutrophil phagocytosis in vitro. 69. The antibody, according to any of the previous modalities, where the antibody does not significantly induce ADCC in vitro. 70. The antibody, according to any of the previous modalities, where the antibody does not significantly induce CDC in vitro. 71. The antibody, according to any of the previous modalities, where the Fc region is IgG 1 (SEQ ID No.: 33), IgG2 (SEQ ID No.: 34), IgG2 / 4 (SEQ ID No.: 35) ), or lgG4 (SEQ ID NO: 36), with one or more of the following point mutations: a. E233P b. L234A or V234A or F234L or F234V c. L235E or L235A d. G236R or G236A e. G237A f. N297Q g. L328R h. A330S i. P331S 72. The antibody, according to any of the previous modalities, where the Fc region is IgG1 or a mutant IgG 1. 73. The antibody, according to any of the foregoing modalities, where the Fc region is a mutant IgG1 Fc comprising 1 to 10 amino acid substitutions compared to the reference IgG 1 Fc, as defined in SEQ ID NO. 33. 74. The antibody, according to any of the foregoing modalities, where the Fc region is a mutant IgG1 Fc comprising 1 to 8 amino acid substitutions in AA 231 to 240 where the IgG 1 Fc reference sequence is as defined in SEQ ID NO. 33. 75. The antibody, according to any of the foregoing modalities, where the Fc region is a mutant IgG1 Fc comprising 1 to 5 amino acid substitutions in AA 328 to 334 where the IgG 1 Fc reference sequence is as defined in SEQ ID NO. 33. 76. The antibody, according to any of the previous modalities, where the Fc region of the antibody is IgG 1, with one or more of the following groups of point mutations: a. N297Q and / or b. L234A and L235E and / or c. G236R and L328R and / or d. N297Q, L234A and L235E and / or e. N297Q, L234A, L235E and G237A and / or f. L234A, L235E, G237A, A330S and P331S 77. The antibody, according to any of the modalities 52 to 76, wherein said antibody is a full-length antibody or an antibody fragment or a single chain antibody. 78. The antibody, according to any of the above embodiments, wherein said antibody is a monoclonal antibody. 79. The antibody, according to any of the foregoing modalities, wherein said antibody is a human, mouse, rat, rabbit, pig, or non-human primate antibody. 80. The antibody, according to any of the above embodiments, wherein said antibody is a mouse or human antibody. 81. The antibody, according to any of the above embodiments, wherein said antibody is a human antibody or a humanized antibody. 82. The antibody, according to any of the foregoing embodiments, wherein said antibody is a human antibody. 83. An antibody, according to any of the foregoing modalities, for the treatment of a disease or immune disorder. 84. The antibody according to claim 83, wherein the disorder is an inflammatory disease. 85. The antibody according to claim 83, wherein the disorder is an acute or chronic inflammation. 86. The antibody according to claim 83, wherein the disorder is an autoimmune disease. 87. The antibody, according to any of modalities 83 to 86, where the antibody is administered intravenously or subcutaneously. 88. The antibody, according to any of modalities 83 to 86, where the antibody is administered in doses from 0.010 mg / kg to 6 mg / kg. 89. The antibody, according to any of modalities 83 to 88, where the antibody is administered once a week or every two weeks. 90. The antibody, according to any of modalities 83 to 89, where the antibody is administered in combination with another drug. 91. The antibody, according to any of modalities 83 to 90, where the disease or disorder is rheumatoid arthritis (RA), psoriatic arthritis, systemic lupus erythematosus (SLE), lupus nephritis, inflammatory bowel disease (Dll), inflammatory bowel disease, Crohn's (DC), ulcerative colitis (CU) or irritable bowel syndrome. 92. The antibody, according to any of modalities 83 to 91, where the patient is being treated with another drug such as methotrexate. 93. A method for treating or preventing a disorder in an individual, comprising administering to a subject in need of treatment a therapeutic amount of an antibody according to any of modalities 1 to 82. 94. The method, according to 93 , where the disorder is a disease or immune disorder. 95. The method, according to modality 93 or 94, where the antibody is administered intravenously or subcutaneously. 96. The method, according to any of modalities 93 to 95, where the antibody is administered in doses from 0.010 mg / kg to 6 mg / kg. 97. The method, according to any of modalities 93 to 96, where the antibody is administered once a week or every two weeks. 98. The method, according to any of modalities 93 to 97, where the antibody is administered in combination with at least one other drug. 99. The method, according to any of modalities 93 to 98, where the disorder is an immunopathological disorder such as an autoimmune disease. 100. The method, according to any of the modalities 93 to 99, where the individual is a patient suffering from rheumatoid arthritis (RA), psoriatic arthritis, systemic lupus erythematosus (SLE), lupus nephritis, inflammatory bowel disease (Dll) , Crohn's disease (CD), ulcerative colitis (CU) or irritable bowel syndrome. 101. The method, according to any of modalities 93 to 101, where the patient is being treated with another drug. 102. A pharmaceutical composition comprising an antibody, according to any one of embodiments 1 to 82, optionally in combination with a pharmaceutically acceptable carrier. 103. The pharmaceutical composition, according to modality 102, in the form of an aqueous formulation or a dry formulation that is reconstituted in water / aqueous buffer before administration. 104. An isolated polynucleotide encoding a polypeptide sequence (s) of an antibody, according to any of modalities 1 to 82. 105. The host cell, comprising one or more polynucleotides according to modality 104. 106. The process to produce an antibody, according to any of embodiments 1 to 82, comprising culturing a host cell according to embodiment 105 under conditions that support the expression of one or more polypeptide sequences of said antibody. 107. The process, according to mode 106, where the heavy chain and the light chain are encoded by two separate open reading frames in a contiguous polynucleotide. 108. The method, according to method 106 or 107, further comprising recovering said antibody from the host cell culture. 109. Use of an antibody, according to any of modalities 1 to 82, for the manufacture of a medicine. 110. Use of an antibody, according to any of modalities 1 to 82, for the manufacture of a medicine for the treatment of an immune disease or disorder such as rheumatoid arthritis (RA), psoriatic arthritis, systemic lupus erythematosus (SLE), lupus nephritis, inflammatory bowel disease (Dll), or irritable bowel syndrome. Examples Example 1: Generation of human anti-hC5aR antibodies Immunization and screening
[000163] In general, raising antibodies against GPCRs is difficult since the soluble protein having the correct native protein conformation is very difficult, if not impossible, to produce. Traditionally, cells overexpressing GPCRs have been used for immunization, but the resulting antibody responses tend to be very non-specific, making it difficult to identify antibodies that have the desired profile, that is, are able to block ligand binding and GPCR signaling. In fact, the inventors found it very challenging to develop human anti-hC5aR antibodies that could block the binding of C5a to C5aR, and a number of immunization strategies were applied before these antibodies were identified.
[000164] HumAb mice (Medarex) were immunized with mouse L1.2 cells (a mouse B cell lymphoma line) with high expression of human C5aR (~ 80,000 copies per cell) (Lee et al., Nat. Biotechnol, 2006; 10: 1279 to 1284) and splenocytes from immunized mice were used for cell fusions using standard procedures. Due to the absence of soluble hC5aR, supernatants could not be screened in a standard ELISA assay, and a cell-based binding assay was then established. The hybridoma supernatants obtained were tested for binding to a transfected rat cell line (RBL) stably expressing a high number (~ 1,000,000 copies per cell) of native hC5aR by FACS analysis, as described in WO 2008/022390. In general, hybridoma supernatants were incubated with a mixture of non-transfected cells (labeled with CelITracker) and cells transfected with hC5aR, or neutrophils from genetically modified / non-genetically modified (KOKI) mice with hC5aR (WO 2005/060739), and incubated with goat anti-human IgG F (ab ') 2 conjugated to APC (IgG-APC). Supernatants that bind to cells transfected with hC5aR but not non-transfected cells have been identified, and hybridomas producing anti-hC5aR have been subcloned and tested for binding to human neutrophils and bone marrow-derived neutrophils isolated from KOKI mice (data not shown). Anti-hC5aR antibodies were purified from hybridoma supernatants using protein A sepharose and standard protocols. Example 2: Identification and characterization of anti-hC5aR antibodies
[000165] As mentioned, the process of obtaining human anti-hC5aR antibodies was problematic, and 32 fusions had to be performed before an hC5a / hC5aR blocking antibody was identified. From 35 fusions and screening of more than 100,000 hybridoma supernatants, only 11 clones that have been identified could block hC5a by binding to hC5aR. The tests applied in the characterization of the antibodies are described below. The reference antibody (Ref. Ab Q) is described in WO 2009/103113. In addition, additional assays suitable for determining affinity and functionality in a calcium flow assay and CD11 b induction are described in Example 7. Removal Assay
[000166] A scintillation proximity assay (SPA) was applied in order to determine the potency of anti-hC5aR antibodies to remove hC5a by binding to hC5aR. A detailed description of the SPA is provided in the US patent. 4,568,649 and protocols provided by the manufacturer (Amersham Biosciences). In summary, membrane fragments carrying receptors purified from RBL-hC5aR cells bind to scintillate microparticles coated with wheat germ agglutinin (WGA). After adding a trace of radiolabeled hC5a (125l), binding to receptors will result in light emission from the particles. Specific to the SPA principle, only radioisotopes and particles in close proximity to each other will emit light. That is, only radiolabeled hC5a attached to a receiver is close enough to a WGA particle to produce light. The amount of light emitted is thus an expression of the amount and 125l-hC5a binding to the receiver. The test is a competition test, in which unmarked anti-hC5aR / hC5a competes with the trait in connection with the receptors. In the test, a fixed amount of 125l-labeled C5a is added to WGA particles and C5aR receptors resulting in the emission of a certain amount of light measured as counts per minute (cpm). If unlabeled or anti-C5aR C5a is added, binding to receptors will cause lower cpm due to the removal of 125l-C5a. The removal% was calculated as follows:
S: sample SmaX: non-specific connection. Measured by adding unlabeled hC5a in an amount sufficient to supplant the specifically bound 125l-hC5a. S0: maximum connection. No unmarked hC5a is added.
[000167] The IC50 value is defined as the concentration that removes 50% of C5a. The cpm was kept constant between the experiments, so the IC50 values are relative as the trace decays over time. The potency (IC50) of human anti-hC5aR antibodies to remove 125l-hC5a was determined and the data are provided in Table 1. Neutrophil Migration Assay (Chemotaxis)
[000168] The potency of the antibodies in inhibiting hC5a-dependent neutrophil migration (or mC5a) was analyzed in a Boyden chamber. Neutrophils isolated from human or animal blood were stained with calcein and added to the upper compartment in Boyden's chamber and mixed with the antibodies. hC5a or mC5a is applied to the lower compartment in Boyden's chamber and acts as a chemoattractant for neutrophils. The ability of neutrophils to migrate to the lower chamber is determined by counting the number of neutrophils colored with calcein passing through a 3 or 5 pm Fluoroblok membrane.
[000169] Human PMNs (polymorphonuclear leukocytes; granulocytes) were obtained from human blood samples taken from EDTA containing weak cells. The blood cells were separated by centrifuging the blood (4 parts) through a Ficoll-Paque PLUS gradient (GE Health Care) (3 parts) for 30 min (400 x g) at room temperature. The PMN-containing layer was suspended in PBS (phosphate-buffered saline) containing dextran-500 (Sigma) for one hour to remove contaminating erythrocytes. The supernatant was centrifuged for 5 min (250 x g) at room temperature and the remaining erythrocytes were osmotically lysed using 0.2% NaCI for 55 s. The solution was made isotonic by 1.2% NaCI + PBS and centrifuged at 250 x g for 5 min, before the osmotic lysis was repeated. After centrifugation, PMNs were resuspended in reaction mixture (RM): HBSS (cat. No. 14175 Gibco) contains 137 mM NaCI, 5.3 mM KCI, 0.33 mM Na2HPO4, 4 mM NaHCOs, KH2PO4 0.44 mM, 5 mM glucose; supplemented with 0.4 mM MgSθ4 * 7H2θ, 0.5 mM MgCh, 0.5 mM CaCh, 20 mM HEPES. Cell density was determined by NucleoCounter (Chemometec). The PMN suspension contained> 95% neutrophils as assessed by microscopy of colored samples with Giemsa.
[000170] PMNs loaded: calcein, AM, (Fluka) was dissolved in DMSO (Dimethyl sulfoxide) and diluted 1,000X in cell RM (2 x 106 cells per ml) to result in a concentration of 10 pM. The suspension was incubated for 30 min in a 37 ° C incubator and then washed 3 times with RM to remove excess calcein. Finally, the cells were resuspended in RM (4 x 10 6 cells / ml).
[000171] Migration was assessed by the Boyden chamber technique using FluoroBlok® of 96 well 3 pm pore size (cat. No. 351161.BD Falcon (VWR)). The upper chamber, that is, the inserts containing Fluoroblok membrane, was coated with human fibrinogen (cat. No. F3879-1G, Sigma) in 1 mg / ml PBS at 37 ° C for two hours. After washing, the membranes were blocked with a solution containing 2% bovine serum albumin (BSA), in PBS. After another wash using RM, 105 PMNs loaded with calcein with or without the antibodies that bind to hC5aR were added to each well and placed in the recipient plate (lower chamber) containing the control solution or the hC5a chemo attractant (Sigma, C5788) . Each group comprised at least 6 cavities. Then, the plate was measured at 485/538 nm, 37 ° C, every 5 min for 60 min in a plate reader (SpectraMax, Molecular devices, or Fluoroscan, Thermo Labsystems). The 30 min value in relative fluorescence units was used in a measurement of migration.
[000172] Curve adjustment. The ability of antibodies to inhibit migration was expressed by IC50 as determined using GraphPad Prism 5 (GraphPad Software, Inc.).
[000173] Table 1 includes data from the removal assay and the chemotaxis assay that tested the ability of 10 pg / ml human mAbs to inhibit hC5a-dependent migration (10 nM) of human neutrophils. The value obtained in the absence of antibody was adjusted to 100. The data were compiled from 3 donations. The mean values are included in Table 1. The three mAbs 32F3A6, 35F12A2 and 35F32A3 showed the strongest potency in both assays, which was equal to or slightly higher than the potency of a Ref. Ab control antibody Q is described in WO 2009/103113.
Table 1. Functional characteristics of anti-hC5aR antibodies. Characterization of anti-hC5aR mAb CDR Sequences
[000174] The variable regions of the anti-hC5aR Abs 35F32A3, 32F3A6, 35F12A2 and 35F24A3 were recombinantly cloned and the nucleotide and amino acid sequences were characterized using standard methods. The amino acid sequences are included in figure 1 and the attached sequence listing. Characterization of the Connection Specificity
[000175] Mouse-human chimeric C5aR constructs were used to determine the C5aR binding region. The chimeric receptors were transiently expressed in HEK cells and the binding of individual antibodies was determined by FACS, as previously described in WO 2008/022390, except for the change in cell line. The binding of 32F3A6, 35F32A3 and 35F12A2 was dependent in human sequence on the extracellular loop 2, with the human N-terminal being dispensable (figure 2). Example 3. Generation of Fc Variants
[000176] The four human IgG subclasses (lgG1, lgG2, lgG3 and lgG4) share more than 95% homology in the Fc regions, but show greater differences in the hinge region. The Fc region mediates effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). In ADCC, an antibody's Fc region binds to activation Fc receptors (FcyRs) on the surface of immune effector cells such as natural killer cells and monocytes, leading to phagocytosis or lysis of target cells. In CDC, the Fc region binds to the complement at a different site than the FcyR binding sites, and antibodies kill target cells by firing the complement cascade on the cell surface. The various isoforms of IgG exert different levels of effector functions, increasing in the order lgG4 <lgG2 <lgG1 <lgG3. A number of IgG Fc variants, comprising the Ref Ab Q variable region, were generated by site-directed mutagenesis using the QuickChange® Site-Targeted Mutagenesis Kit (Cat. No. 200518, Stratagene) and featured as described in Example 4. Example 4: Characterization of effector functions of Fc variants Binding affinity of Fc variants with FcyRs
[000177] The affinity of the Fc variants towards FcyRs was determined by surface plasmon resonance (SPR) measurements that were performed on a BIAcore T100 instrument using a CM5 (GE) sensor chip. The Fc variants were immobilized in flow cells using amine coupling chemistry. For kinetic SPR measuring the affinity of FcyR to Fc variants, His-FcyRs were used as analytes and were injected into flow cells in HBS-EP buffer. The high affinity FcyRI receptor was injected with a flow rate of 40 pl / min, a contact time of 180 seconds, and a dissociation time of 300 seconds. The other FcyRs were injected with a flow rate of 50 pl / min, a contact time of 30 seconds, and a dissociation time of 120 seconds. The surfaces of the chips were regenerated with a solution containing 10 mM NaOH and 500 mM NaCI. The affinities (Kd values) are listed in Table 2A.


[000178] Table 2A. Summary of results obtained from the analysis of the affinity of the Fc variants towards FcyRs (Kd in M). (- = no connection; 0 = no change in connection; nda = Kd not calculated due to very weak connection). (1) an Fc variant of lgG2 / lgG4 comprising CH1 and the lower hinge region of lgG2, and the remaining CH2-CH3 of lgG4; (2) lgG4 mutant including the S228P point mutation. Phagocytosis Assay
[000179] In order to identify Fc variants with reduced or abolished capacities to mediate neutrophil phagocytosis, an in vitro phagocytosis assay has been established. The phagocytosis assay described below involves labeling human neutrophils isolated from peripheral human blood (the target cell for phagocytosis) with a fluorescent dye, CMFDA, and adding them to a culture of human monocytes, also isolated from human peripheral blood. CMFDA-labeled neutrophils are pre-coated with test mAbs (or PBS) and after incubation with human monocytes, the number of CD14 / CMFDA double positive monocytes is determined by FACS. The results of several Fc variants are shown in Table 2B.
[000180] All antibodies tested include the variable regions of the Q antibody described in WO 2009/103113 and used as Ref Ab above.
[000181] Both monocytes and macrophages proved to be able to mediate antibody-dependent neutrophil phagocytosis, and phagocytosis assays using both cell types were established. The results were qualitatively similar in both assays, but as the macrophage assay was more variable, the analysis was mainly performed using monocytes. Preparation of Human Monocytes
[000182] Human monocytes and lymphocytes were isolated from peripheral venous blood collected from healthy human volunteers in tubes containing EDTA as an anticoagulant (K2E, BD Biosciences, Cat. No. 367525) using percoll gradient centrifugation. 100 ml of blood usually supplies ~ 8 to 20 x 107 peripheral blood mononuclear cells (PBMCs). At least 3 volumes of dPBS were added to the isolated cells which were then centrifuged at 100 x g for 10 min at room temperature (RT). After discarding the supernatant, the lymphocyte / monocyte layer was resuspended in the same volume of a 50:50 mixture of dPBS: culture medium as the previous step and centrifuged again at 100 x g for 10 minutes in RT. The supernatant was discarded and the lymphocyte / monocyte layer resuspended in 1 to 2 x 106 cells / ml in culture medium. The resuspended cells were placed in 6-well tissue culture plates (Corning, Costar Cat. No. 3516) in 2 ml / well with 4 x 106 cells / well and incubated for 2 hours at 37 ° C in 5% CO2 . Non-adherent cells (lymphocytes and dead cells) were removed by aspiration and the adhered cells (monocytes) were washed four times in 1 ml of culture medium (RPMI 1640 (Invitrogen-GIBCO, Cat. No. 11875) + 10% FCS ( Invitrogen-GIBCO, Cat. No. 16000) heat inactivated at 56 ° C for 30 min + 25 mM Hepes (Invitrogen-GIBCO, Cat. No. 15630) + 1% Pen / Strep (Invitrogen-GIBCO, Cat. No. 15070)) with a gentle swirl before aspirating the washing medium. After washing the blood-derived monocytes, 1 ml of fresh culture medium was added to each well. The cells were scraped from a well and suspended in culture medium in order to estimate the number of monocytes per well. Preparation of Human Neutrophils
[000183] Human neutrophils were isolated from peripheral venous blood collected from healthy volunteers using percoll gradient centrifugation and stained with CellTracker ™ Green (5-chloromethylfluorescein diacetate, CMFDA). 100 ml of blood usually provides ~ 10 to 20 x 107 neutrophils. Staining was performed by dissolving CellTracker ™ green CMFDA in DMSO to a final concentration of 10 mM. Neutrophils were resuspended in 1 x 10 7 cells / ml in dPBS and CMFDA was added to a final concentration of 2 pM. The cells and the dye were incubated for 15 min at 37 ° C. The excess dye was removed by washing the cells 3 times with 10 ml of dPBS (by centrifugation at 300 x g for 5 min in RT). A cell count was performed after the last washing step. CMFDA-labeled neutrophils were resuspended in 2 x 106 cells / ml in dPBS and incubated with antibody (final concentration 0.001, 0.01, 0.1, 1, 10 or 100 pg / ml) or PBS (without antibody control) . In some assays (as indicated), the neutrophil + Ab incubation step also contained 4 mg / ml of human IgG. The cells plus antibody were incubated for 30 min at 37 ° C. Neutrophils were washed twice with dPBS after centrifugation at 300 x g for 5 minutes in RT and resuspended in culture medium at 1 x 107 cells / ml. FACS Analysis
[000184] CMFDA-labeled neutrophils, pre-coated with antibody (prepared as described above) were added to the monocytes (as described above) in the desired concentration in 1 ml of culture medium. The total volume in each well of the 6-well plate was 2 ml. In some assays (as indicated), the culture medium also contained 4 mg / ml of human IgG. A 5: 1 ratio (neutrophils: monocytes) was generally used. If the number of adherent monocytes was less than 4 x 105 per well, then 2 x 106 neutrophils were added (ie, the neutrophil: monocyte ratio exceeded 5: 1). If the number of monocytes exceeded 4 to 105 per well, then five times that number of neutrophils was added to maintain the neutrophil: monocyte ratio at 5: 1. The cultures were incubated for one hour at 37 ° C in a 5% CO2 incubator.
[000185] After incubation, the medium was aspirated to remove non-adherent and ingested neutrophils. Adherent monocytes were washed (with a gentle swirl) three times with 1 ml / well of culture medium. Monocytes were collected in 15 ml tubes by scraping cells in culture medium from the wells with cell scrapers (Corning, Cat. No. CP3010). The cells were centrifuged at 300 x g for 5 min in RT and the supernatant removed. The cell pellet was resuspended in 160 pl of 1% paraformaldehyde (weight / volume) in PBS to fix before FACS.
[000186] The samples were analyzed on a FACSCalibur flow cytometer (BD Biosciences). CMFDA-labeled neutrophils were identified and measured in FL-1 (fluorescence channel 1) using fluorescein isothiocyanate (FITC), and monocytes identified by staining a sample of monocytes only with phycoerythrin-labeled anti-CD14, which was measured in FL-2 (fluorescence channel 2). A monocyte port was defined using the FSC profile (frontal light scattering) against SSC (lateral light scattering) of the monocyte-only sample and enlarged (along the FSC and SSC axes) to include monocytes whose size increased during incubation . This port excluded the region of the FSC profile against SSC containing neutrophils as defined in the FSC profile against SSC in a sample of neutrophils only. The extent of phagocytosis was calculated as the percentage of FL-1 + ve monocytes in the total monocyte port.
[000187] The baseline level of non-specific phagocytosis was the percentage of FL-1 + ve monocytes in a sample containing CMFDA-labeled neutrophils not coated with antibody ("non-Ab" sample). The base was subtracted from each sample with Ab before the data (% of monocytes FL - 1 + ve against Ab) were inserted into a Prism software (v4.0c, GraphPad Software Inc). The data were submitted to non-linear regression using the sigmoidal dose-response curve, that is, the logistic equation of 4 parameters, in order to determine the EC50 values where appropriate.
[000188] The data are presented in Table 2B. represents undetectable phagocytosis and "+" to "++++" represents low to high level of phagocytosis, as measured in the tests.
[000189] ADCC (antibody dependent cell cytotoxicity) and CDC (complement dependent cytotoxicity) assays
[000190] The following in vitro assays were established in order to test the ability of the Fc variants to mediate cell depletion via ADCC or CDC dependent mechanisms. Target Cells
[000191] In these assays, the target cells were hC5aR expressing clone Ramos E2 or human neutrophils. The Ramos E2 clone expressing hC5aR was developed by stably transfecting Ramos E2 clone cells with a mammalian expression vector encoding hC5aR using standard procedures. The resulting cell line expresses high levels of human C5aR (5 to 7 times higher than human neutrophils) and CD20. Human neutrophils were obtained as described above in relation to the phagocytosis assay.
[000192] The target cells were stained with the fluorescent cell membrane dye, PKH-26. The required number of target cells (5 x 104 / sample / well x 4) was diluted in 15 ml of dPBS and centrifuged at 1,200 rpm for 5 min in RT. The cells were then resuspended in 2 µM PKH-26 (100 µl of solution for each 1 x 10 6 target cells). The labeling was continued at room temperature for exactly 3 min before an equal volume of heat-inactivated FCS (or heat-inactivated human serum (Millipore)) was added to stop the labeling reaction. After exactly 1 min, RPMI was added to a total volume of 15 ml. The cells were centrifuged as above and resuspended at 2 x 10 6 cells / ml in assay medium. For coating with antibody aliquots (25 pl, ie, 5 x 104) of PKH-26, labeled target cells were dispensed into wells of a 96-well sterile U-bottom plate containing 25 pl of 200 pg / ml of antibody diluted in assay medium (final concentration 100 pg / ml) and incubated at 37 ° C in 5% CO2 for 30 min. Effector Cells
[000193] Effector cells were monocyte depleted PMBCs from healthy donors. PMBCs were obtained as described above. The resuspended cells (lymphocytes / monocytes) were placed in 6-well tissue culture plates (Corning) in 2 ml / well with -4 x 106 cells / well or T75 flasks (Corning) in 20 ml per flask and incubated for 2 hours at 37 ° C in 5% CO2. Non-adherent cells (including lymphocytes and NK cells) were removed by aspiration and centrifuged at 100 x g for 10 min in RT. The cells were resuspended in 20 ml of medium containing 100 ng / ml of recombinant human IL-2 to increase the number of lymphocytes and natural killer cells. The cells were incubated overnight at 37 ° C in 5% CO2. The next day, the cells were centrifuged at 1,400 rpm for 10 min in RT and then resuspended in assay medium at 2.5 x 10 7 cells / ml for use as effector cells in the ADCC assay. ADCC Assay
[000194] After labeling target cells with PKH-26 and coating with antibody, 100 µl of effector cells or 100 µl of assay medium (control, target cell only) were added directly to 50 µl of target cells. The samples were incubated for an additional 3 hours at 37 ° C in 5% CO2. The samples were transferred to 1.2 ml of microtiter FACS tubes containing 10 µl of 10 pM To-Pro-3 viability dye (TP-3) to a final concentration of -625 nM and the samples were analyzed by FACS. On an FSC versus SSC graph, all cells excluding debris were captured. Captured cells were analyzed in FL-2 against FSC and positive FL-2 cells (i.e., target cells labeled PKH-26) were captured. The FACS data were analyzed using FlowJo software (Tree Star, Inc. v6.3.4).
[000195] Specific ADCC was calculated by subtracting the average% of TP3 + ve'Targets Only '(A) from the average% of TP3 + ve'Targets + Effectors' (B) of corresponding samples after subtracting the average% of TP3 + ve'Sem Ab Targets Only '(C) and average% of TP3 + ve'Sem Tar Ab + Effectors' (D) respectively; that is, specific ADCC = (B - D) - (A - C) or = (B - A) - (D - C) Equation 1
[000196] The results shown in Table 2B were obtained using monocyte-depleted PBMCs, IL-2-stimulated human PBMCs, predominantly NK cells, but including B cells, T cells and dendritic cells, as the effector cell population. The target cells were a line of transfected Ramos E2 cells expressing both hC5aR and CD20 enabling the use of the anti-CD20 antibody rituximab as the positive control. The results are in the "+++" range which is indicative for an Fc variant inducing ADCC with potency equal to that of Rituximab, which is indicative for an Fc variant for which a high degree of donor variation has been observed and which is indicative for a variant of Fc for which no significant induction of ADCC has been detected. An FCC variant mediating increased ADCC (lgG1_S239D, I332E) (Chu SY, Vostiar I, Karki S and others; Mol Immunol, 2008, 45 (15): 3926 to 3933) was included as a positive control for the assay. CDC Assay
[000197] Fc variants were also analyzed for their potency to induce CDC. The experimental setup was essentially as described for the ADCC assay, except that the effector cells were replaced with human serum.
[000198] Target cells, such as Ramos E2 cells (2 x 106 cells / ml) in medium with 3% rabbit complement serum were mixed with an equal volume of 2x antibody solution (200 pg / ml) containing 3% rabbit complement serum in a 96-well U-bottom tissue culture plate. A duplicate set of wells contained 25 µl Ramos E2 cells (2 x 10 6 cells / ml) mixed with 25 µl 2x antibody solution (200 µg / ml) in medium without complement. A set of 3 wells contained 25 pl of Ramos E2 cells (2 x 106 cells / ml) plus 25 pl of assay medium (samples 'without Ab') in 3% Rabbit Complement Serum. Another set of 3 wells contained 25 pl of Ramos E2 cells (2 x 106 cells / ml) plus 25 pl of assay medium (samples 'without Ab') without complement. Prior to incubation, 100 µl of assay medium, with or without 3% rabbit complement serum as appropriate, was added to each well. The samples were incubated for 3 hours at 37 ° C in 5% CO2. Determination of Target Cell Viability
[000199] The fluorescent viability dye To-Pro-3 (Molecular Probes), was added to each sample immediately before analysis by flow cytometry. The final concentration of To-Pro-3 in each tube was ~ 62.5 nM. To-Pro-3 positive cells (TP3 +) were defined as not being viable or lysed. Flow Cytometry and Data Analysis
[000200] The samples were analyzed on a FACSCalibur (BD Biosciences) and the acquired data were analyzed using FlowJo software (v6.3.4, TreeStar Inc.). In the FSC versus SSC diffusion graph, capturing all cells, excluding debris, 5,000 target cell events were collected for each sample. A histogram of the target cells captured in the FL-4 channel that was created showed the level of absorption of To-Pro-3 by the cells. The number of TP3 + cells (ie, non-viable cells) in each sample was determined - these were defined as cells on the right side of the main peak - and that number was expressed as a percentage of the total target cells in the sample.
[000201] The samples, tested in triplicate, could be classified into one of 4 categories A, B, C and D, as shown in the Category Overview below. Category Overview
Sample categories analyzed
[000202] For each sample that contained antibody, the reactions were performed with or without complement. Samples containing antibody without complement provided the level of specific antibody background lysis. Samples in categories B and D provided nonspecific background lysis in the absence of either antibody or antibody and complement.
[000203] The percentage of non-viable TP3 + target cells (% lysis) was calculated for each sample with 3% complement and for each sample without complement. For each antibody and control 'without Ab', data from triplicate samples were averaged.
[000204] To calculate the specific CDC activity for each antibody, the specific antibody lysis in the absence of complement (mean% lysis in samples' A ') was subtracted from the% lysis of sample Ab with complement (samples' C1 / 2 / 3 ') before subtracting nonspecific background lysis. Non-specific background lysis was lysis in samples 'without Ab' with complement (average% lysis in samples 'D') less lysis in samples 'without Ab' without complement (average% lysis in samples 'B'). The Fc variant mediating increased CDC (lgG1_S254W) (W008030564) was included as a positive control for the assay. Specific CDC (% of lysis) = (C - A) - (D - B) [ou = (C - D) - (A - B)] Equation 2
[000205] Statistical analysis was performed on GraphPad Prism (v4.0) to determine if the differences between any of the groups were significant. The specific CDC activity of each sample from all 4 assays was entered in a spreadsheet according to the antibody used. The groups were compared using a parametric test: one-step analysis of variance (ANOVA) followed by Tukey's multiple comparison test.
[000206] The results are included in Table 2B. The results are in the range of "+++" which is indicative for a variant of Fc including CDC with a power equal to lgG1 S254W mutant. which is indicative for a variant of Fc for which a high degree of variation has been observed and which is indicative for a variant of Fc for which no significant induction of CDC has been detected.


[000207] Table 2B. Activity of Fc variants in cell-based effector function tests.
[000208] Summary of the results obtained from the analysis of the Fc variants in phagocytosis, ADCC and CDC assays. (- = without effector function; + = effector function). (1) an IgG2 / IgG4 Fc variant comprising CH1 and the lower hinge region of IgG2, and the remaining CH2-CH3 of IgG4; (2) S228P mutation introduced in the Fc region of IgG4 in order to eliminate the formation of antibody media. Example 5: Characterization of the potency of anti-hC5aR antibody Fc variants
[000209] In order to test whether mutations in the Fc region affect the potency of the antibodies to inhibit hC5aR binding and hC5a-mediated neutrophil migration, respectively, the different Fc variants were tested in the removal and migration assays described above . The neutrophil migration assay was performed as described above, except that the PMNs used were PMNs from mice isolated from KO / KI mice with hC5aR (genetically modified with mC5a receptor / not genetically modified with human C5aR, WO 2005/060739). The cells were obtained as follows. Bone marrow PMNs were isolated from the femurs and tibiae of two KOKI mice with hC5aR. The marrow cells were purged from the bones using PBS before cell suspension was filtered through a Cell Strainer (BD Falcon, 352350; 70 micron nylon mesh) in a 50 ml tube and centrifuged (10 min, 1600 rpm). The cells were resuspended in medium and carefully layered on top of 3 ml of Ficoll-Paque PLUS (GE Heathcare) in a sterile 15 ml tube. After centrifugation for 20 minutes at 600x g at room temperature, the neutrophil / erythrocyte pellet is isolated. Erythrocytes are lysed using Lysis Buffer (Sigma, R7757; 8.3 g / L ammonium chloride in 10 mM Tris-HCI pH 7.5) for 1 min. After two stages of centrifugation and washing, the cell pellet is resuspended in a reaction mixture. The suspension contained> 95% neutrophils as assessed by microscopy of colored samples with Giemsa. The variable region of the tested antibodies was identical to the variable region of Ref. Ab Q. Data are provided in Table 3.
[000210] A significant difference in potency in inhibiting hC5a by binding to hC5aR was observed for the Fc variants in the SPA analysis (Table 3, column 1). An lgG1 version of Ref. Ab Q was analyzed along with additional IgG Fc variants, and the data showed that IgG 1 Fc variants, in general, inhibited hC5a binding more potently than both Fc variants of lgG4 and lgG2 / lgG4. An F (ab ') 2 fragment from Ref. Ab Q was also included in the analysis and was found to inhibit hC5a binding to the same degree as Ref. Ab Q in full length (IgG4). These conclusions indicated that the hinge region is important for the ability of antibodies to inhibit hC5a binding and this notion was supported by the fact that F (ab ') 2 fragments were able to inhibit the migration of neutrophils to the same degree of Ref Ab Q (Table 3). Also, lgG1 variants proved to be more potent in inhibiting neutrophil migration than IgGs comprising hinge regions of lgG2 or lgG4 (Table 3, column 2).
[000211] The greater power of lgG1 versions of Ref. Ab over lgG4 versions could refer to the increased avidity due to the increased flexibility of the IgG hinge region. To investigate this, the binding of the lgG1 and lgG4 versions of Ref. Ab to human neutrophils was analyzed by FACS. The data demonstrated that the IgG 1 version bound to neutrophils with greater avidity than the IgG4 version. The data is not shown.
[000212] Used together, these conclusions support that the increased flexibility in the lgG1 hinge regions contribute to the increased binding to hC5aR, which leads to the increased power.

[000213] Table 3. Effect of Fc variants on hC5a binding (SPA) and migration of neutrophils towards hC5a. (+ = low activity, ++ = medium activity, +++ / + high). Example 6. Generation and characterization of "completely" human anti-hC5aR antibodies
[000214] From the analyzes described in Example 2, the 32F3A6 antibody was selected for further studies. During recombinant cloning of this antibody, seven mutations in the VH structure region that differed from human germline sequences were identified, while no structure mutation was found in the LC (figure 3). The mutations were found by aligning the 32F3A6 VH and VL sequences for all available human germline sequences.
[000215] In order to make the antibody even more similar to the human, the seven point mutations in the VH region of 32F3A6 were mutated again to the human germ line residues, and grafted into the Fc region of IgG 1 comprising the five L234A_L235E_G237A_A330S_P331S mutations that showed abolish induction of phagocytosis, ADCC and CDC, as described above. The compound is called 32F3A6 GL. The potency of the mutated antibody again was compared with the original antibody and no difference was observed in the potency in inhibiting hC5a binding to hC5aR (assayed in SPA) or in the potency in inhibiting hC5a-mediated neutrophil migration between 32F3A6 or 32F3A6 GL.
[000216] The ability of the fully human antibodies described above to induce neutrophil phagocytosis, ADCC or CDC was assessed as described in Example 4 and the results are summarized in Table 4.
[000217] Results regarding specific ADCC included in Table 4 were obtained using monocyte-depleted human PBMCs as effector cells, and human neutrophils as the target cells.

[000218] Table 4. Fc-mediated cellular effector functions of anti-C5aR antibodies.represents no detectable effector function and "+" to "+++" represents low to high level of effector functions, measured in the tests described in Example 4. ND (Not determined).
[000219] As previously noted, the 5 point mutations in the IgG 1 Fc region abolish phagocytosis, ADCC and CDC compared to the naturally occurring Fc lgG1 region. Example 7. Additional characterization of human anti-hC5aR antibody (32F3A6 GL).
[000220] To further elucidate the functionality of the identified antibodies and determine affinity and potency, additional assays were performed using one of the anti-C5aR antibodies compared to Ref AB Q. Affinity was determined by the ligand binding competition assay in human neutrophils. This functionality is called antibody affinity measured by ligand binding competition assay, but it could also be considered a measure of the avidity of the interaction. Ex vivo assays measure the ability of antibodies to neutralize C5a-mediated actions in in vitro configuration. The power tests measured the neutralization of Ca flow induced by C5a, induction of CD11b receptor and regulation of the repression of CD62L, respectively, in human neutrophils. The data obtained for 32F3A6GL are given in Table 5. Affinity measurements Isolation of neutrophils from fresh human blood
[000221] The blood was diluted 1: 1 with PBS + 2% FBS and layered in Ficoll-Paque PLUS (GE Healthcare # 17-1440-03) in a ratio of 3 parts of Ficoll and 4 parts of blood (15 ml of Ficoll and 20 ml of blood in a 50 ml tube) and subsequently stratified by centrifugation at 400 xg for 30 minutes in RT. By aspiration, the intermediate PBMC band was gently removed. Granulocytes and red blood cells were transferred and pelleted in a new 50 ml tube. The pellet was diluted in 40 ml with 1 x PBS and 10 ml of a solution of 4% DEXTRAN 500 (sigma, 31392) in PBS (1: 5 ratio) were added and mixed gently by inversion. After 20 to 30 min, the supernatant rich in granulocytes was transferred to a new tube and rapidly centrifuged at 250 x g for 5 min in RT. The contaminating red blood cells were removed with osmotic lysis by resuspending the cell pellet in 7.5 ml of 0.2% NaCI and gentle mixing for 55 to 60 seconds. Subsequently, 17.5 ml of 1.2% NaCI was added and then diluted in 50 ml with PBS and centrifuged quickly at 250 x g for 5 min. This step was repeated once. The cell pellets were subsequently resuspended in 1 ml of reaction mixture (dPBS / RPMI). Viability and cell counts were monitored using NucleoCounter®. Ligand Binding Competition Assay in Neutrophils
[000222] Human neutrophils were purified, washed and resuspended in binding buffer (50 mM HEPES, pH 7.5, 1 mM CaCh, 5 mM MgCh and 0.5% bovine serum albumin (Fraction V free IgG) ) at ~ 5 x 106 cells / ml. For each sample, 40 µl of cell suspension (1 x 105 cells / well) was seeded in a 96-well V-shaped plate (Greiner, Cat. # 651101). Competition studies were done using 12 concentrations of unlabeled competition ligand in half-log dilutions starting with 1 pM as the highest concentration. 40 µl of antibody was added considering a final assay volume of 120 µl. 40 pl of [125l] -hC5a radioligand (Perkin Elmer, Cat. NEX250) was added to all samples except the background control. The final concentration of the radioligand in the assay was 1 nM and the final volume was 120 pL. All samples were used in triplicate and incubated for 4 hours at 4 ° C. The cells were then collected by centrifugation at 1200 rpm, at 4 ° C for 2 min and washed three times in 100 µl wash buffer (50 mM HEPES, pH 7.5.1 mM CaCh, 5 mM MgCh, 150 mM NaCI and 0.5% bovine serum albumin (Fraction V of free IgG)). Finally, the cells were resuspended in 30 µl wash buffer and transferred to an OptiPlate (Perkin Elmer, Cat. No. 6005290) and 150 µl MicroScint 20 (Perkin Elmer, Cat. No. 6013621) were added to each well. The plates were covered, mixed well and counted on a Top Counter calibrated with an hour delay. The total amount of radioligand added to the assay was determined on a separate plate. The number of counts in each sample that was expressed as normalized values as a percentage was 100% and is the maximum level of counts where 1 nM of [125l] -hC5a and non-cold antibody is added, and 0% is the non-specific binding determined in the presence of 1 pM cold hC5a. The data were analyzed by non-linear regression using PRISM (GraphPad). Calcium Flow Assay Staining of human neutrophils with Fluo-4 AM cell dye
[000223] The neutrophils were centrifuged and washed in PBS and then resuspended in 1 x 107 cells / ml in cell dye and incubated at room temperature for 40 min in the dark. The cells were centrifuged and washed (to remove excess dye), centrifuged again and resuspended in 2 x 106 cells / ml in cell buffer. The cells (0.5 ml) were aliquoted in non-sterile glass FACS tubes - one tube for each sample - stored at room temperature and used within two hours. Each sample used 1 x 106 neutrophils. Test
[000224] The calcium flow test was performed as follows. In summary, 1 x 10 6 neutrophils loaded with Fluo-4 AM in 0.5 ml of cell buffer were analyzed on a FACSCalibur flow cytometer (BD Biosciences) with captured neutrophils using x-axis FSC against y-axis SSC. The FL-1 channel (FITC) was used to measure fluorescence of neutrophils after adding several reagents to the tube (eg, antibodies, C5a, ionomycin - dissolved in 10x the final concentration in cell buffer instead of l-MGB or C -MGB). Sample fluorescence was measured continuously with a mean fluorescence intensity (MFI) value acquired every 1 second. These data were saved in a CelIQuest file (BD Biosciences) and transferred to Excel (Microsoft) and Prism (v4.0c, Graph Pad Software, Inc.) for further processing and analysis. The order of addition of the reagents to the neutrophils and the incubation times varied according to the type of test performed. C5a Neutralization Assay
[000225] Three 10x serial dilutions of the antibody, with concentrations ranging from 1000 pg / ml to 1.37 pg / ml, were prepared. Neutrophils loaded with Fluo-4 AM (1 x 106 in 0.5 ml of cell buffer) were incubated with 50 µl of 10x antibody solution (final Ab concentration in the tube: 100 to 0.137 pg / ml) for 10 min at room temperature . The cells plus antibody were analyzed by FACS for ~ 60 seconds to establish basal fluorescence. Then, 50 µl of 10 nM C5a was added to obtain a final concentration of ~ 1 nM and the fluorescence measurement continued for another ~ 60 seconds. If the antibody blocked C5a-induced Ca2 + release, there was no fluorescence peak. If the antibody did not neutralize C5a, then there was a peak in fluorescence. Finally, 50 µl of 1 pg / ml of ionomycin was added to a final concentration of 0.1 pg / ml and the fluorescence measurement continued for another ~ 60 seconds to ensure that the cells were still responsive. CD11 Receiver Induction b Assay Configuration
[000226] The following configuration was designed to determine the ability of the identified antibodies to neutralize C5a-induced neutrophil activation by measuring changes in CD11b expression.
[000227] Anti-C5aR and isotope control antibody was diluted in PBS at 2x the final concentration in a 3-fold serial dilution (from 600 to 0.003387 pg / ml) and 50 pl dispensed in duplicate in bottom plate wells U-shaped with 96 wells. A 50 pl aliquot of heparinized whole blood was added to each well. Four sets of control wells (in duplicate) contained 50 pl of PBS plus 50 pl of blood only. The plates were incubated for 20 min at 37 ° C in a 5% CO2 incubator. To activate the neutrophils, 50 µl of human C5a, 10 or 100 nM final concentration as specified, were added to the wells containing Ab and a set of control wells without antibody. PBS (50 µl) was added to a second set of control wells without antibody. Phorbol myristate acetate (PMA), final concentration of 5 pg / ml, was added to a third set of control wells without antibody. The plates were incubated again for 20 min at 37 ° C in a 5% CO2 incubator. Finally, 50 µl of a mixture of anti-CD11b-PE (BD Biosciences, Cat. No. 555388) diluted 1/50 in PBS (final concentration 1/200) was added to all wells (except 0 4 ° Set of 2 control wells without Ab and without C5a or PMA - these samples provided baseline MFI values). The plates were incubated again for 20 min at 37 ° C in a 5% CO2 incubator, then centrifuged for 3 min at 2,000 rpm to pellet blood cells. The supernatant (150 pl) was removed and the pellets resuspended in 200 pl 1 x FACS lysis solution to lyse the red blood cells. After 5 min at room temperature, the plates were centrifuged again, 200 to 225 pl of supernatant were removed and the pellets resuspended in 160 pl 1 x FACS lysis solution. The cells were transferred to microtiter tubes for analysis by flow cytometry. FACS and Data Analysis
[000228] The FACSCalibur flow cytometer (BD Biosciences) was configured with compensation parameters established for the FL-2 channels. The samples were captured to exclude dead cells and debris. Neutrophils were identified as having high FSC and SSC and were captured. The mean fluorescence intensity (MFI) of the neutrophils captured in the FL-2 channel (CD11b-PE) was calculated.
[000229] The results were expressed as a percentage of maximum CD11b expression with subtracted background. The maximum CD11 b expression (MaxCD11 b) was the mean MFI of the neutrophils incubated with C5a, but without Ab. The minimum CD11 b expression (background) was the mean MFI of the neutrophils incubated without C5a and without Ab. The formula used to calculate the maximum% CD11b expression for each sample was:% MAX sample = (MFI sample ~ MFIMÍH) / (MFI | Vlax — MFIMÍH) X 100
[000230] The data were entered into the GraphPad Prism (v4.0) and adjusted to the sigmoidal dose-response curve (variable slope), that is, a 4-parameter logistic equation using non-linear regression to calculate the EC50. Suppression of CD62L receptor Assay configuration
[000231] The following configuration is designed to determine the ability of the identified antibodies to neutralize C5a-induced neutrophil activation by measuring changes in CD62L expression.
[000232] The CD11 b assay above was adapted for the detection of CD62L using a conjugated antibody recognizing CD62L (BD Biosciences, Cat. No. 559772). The specific experimental details for CD62L are given below. FACS and data analysis
[000233] The FACSCalibur flow cytometer (BD Biosciences) was configured with compensation parameters established for the FL-4 channel. The samples were captured to exclude dead cells and debris. Neutrophils were identified as having high FSC and SSC and were captured. The mean fluorescence intensity (MFI) in the neutrophils captured in the FL-4 channel (CD62L-APC) was calculated.
[000234] The results were expressed as a percentage of maximum CD62L expression with subtracted background. The maximum expression of CD62L (MaxCD62L) was the mean MFI of the neutrophils incubated without C5a and without Ab. The minimum CD62L expression (background) was the mean MFI of the neutrophils incubated with C5a, but without Ab. The formula used to calculate the maximum% CD62L expression for each sample was:% MAX sample = (MFI sample - MFlMin) / (MFIlVIax— MFlMin) X 100
[000235] The data were entered into the GraphPad Prism (v4.0) and adjusted to the sigmoidal dose-response curve (variable slope), that is, a 4-parameter logistic equation using non-linear regression to calculate the EC50. The results of the above tests are summarized in Table 5 below.

[000236] Table 5. Data obtained from affinity assay, calcium flow assay, CD11 b and CD62L assay.
[000237] The data confirmed that 32F3A6 GL inhibits the action of C5a in a dose-dependent model. The inhibition of Ca2 + release in neutrophils increased with increasing concentrations of 32F3A6 GL and with greater efficiency than Ref. Ab Q, as seen by the lower IC50 value.
[000238] Similarly, 32F3A6 GL is also more effective than Ref. Ab Q in the CD11 b and CD62L regulation assay exhibiting power 4 to 5 times greater than Ref. Ab Q.
[000239] The 32F3A6 GL test in the neutrophil migration (chemotaxis) assay also showed dose-dependence with an IC50 of 1.0 pg / ml. Example 8. In vivo mouse arthritis model
[000240] The in vivo effect was tested in a K / BxN model in KO / KI mice with hC5aR (WO 2009/103113 and Lee et al., Nat. Biotechnol. October 2006; 24 (10): 1279-84). K / BxN mice spontaneously developed a circulating Ab-mediated autoimmune disease against GPI (autoantigene glucose 6-phosphate isomerase). Serum from arthritic K / BxN mice induces the disease in other mouse strains with many characteristics of human AR signs including chronic progressive disease with joint destruction. Animals
[000241] Transgenic KO / KI mice with human C5aR (C57BL / 6; H-2b; human C5aR + / + / C5aR - / - mouse; short for strain: H5Rtg) aged 8 to 27 weeks, K / BxN serum
[000242] To produce serum from the experiments, male KRNtg mice were crossed with female NOD mice. The F1 offspring (8 to 10 weeks of age) carrying the KRN transgene, which developed inflamed joints, was sacrificed and blood was collected by cardiac puncture. After 2 hours of incubation at 37 ° C and centrifugation for 10 min at 4,000 rpm, the serum was collected. Serum from multiple mice was pooled, aliquoted and stored at -80 ° C. All mice were injected with the same lot of K / BxN serum. Arthritis Induction and Score
[000243] An inflammatory arthritis was induced in recipient H5Rtg mice by injecting 150 pl of K / BxN ip serum on both day 0 and day 2. The disease progress was monitored daily by measuring the paw size and determining if the score is based on the degree of inflammation in the front and rear legs and ankle joints. The change in mean paw size on day 0 was calculated as follows. The thickness (in mm) of the ankles on each of the hind legs was measured daily using forceps. The average of one or two daily readings for each hind leg was the average paw size (PS). The average paw size on day 0 was subtracted from the average daily paw size to obtain the average change in paw size (ΔPS) for each day of the experiment. A clinical score was calculated for each paw of each mouse based on the scoring system shown in Table 6. The score of the 4 paws was added to obtain the total clinical score (CS) for each mouse on each day of the experiment.

[000244] Table 6. Arthritis clinical scoring system
[000245] To determine which mouse entered the treatment phase on day 5, an "RA score" was calculated for each mouse by multiplying the clinical score by changing the paw size from day 0 (in mm). Generally, only mice that had an RA score> 0.7 were included in the treatment stage of the study. Therapeutic Treatment with 32F3A6 GL
[000246] After disease onset (day 0), KO / KI mice with hC5aR were given a loading dose of 32F3A6 GL on day 5 and then 9 daily doses. The attack dosages were 10.1.5 and 0.5 mg / kg and the daily dosages 2, 0.5 and 0.25 mg / kg. The clinical scores (mean +/- SD) for each treatment group are shown in figure 4. Treatment with NNC0215-0384 produced a dose-dependent reduction in inflammation compared to mice treated with an irrelevant control antibody. A similar effect was observed based on changes in the average paw size (not shown). Example 9. C5a expression level in patients with psoriatic arthritis
[000247] C5a was measured in samples of synovial fluid from 11 patients with psoriatic arthritis and 12 patients with osteoarthritis as controls. The protocol of a commercial C5a ELISA kit was followed (BD OptEIA ™, ELISA kit with human C5a II (BD Biosciences; cat. No. 557965)). The data are provided in figure 5 and summarized in Table 7 below. The level of C5a was significantly elevated in the group of patients with psoriatic arthritis (p = 0.001; Mann-Whitney) indicating that C5a may be a trigger for synovial inflammation in psoriatic arthritis.

[000248] Table 7. Levels of detection of C5a in the synovial fluid of controls and patients with psoriatic arthritis. Example 10. Expression of C5aR in the synovium of patients with psoriatic arthritis
[000249] Tissue microarray (TMA) slides containing synovial biopsies fixed in fixed formalin and embedded in paraffin from PsA patients (n = 9), and within normal limits (n = 5) were obtained from Biochain Institute Inc. / BioCat GmbH, Heidelberg, Germany. A sample of PsA from the collaboration with Dr. Bliddal (Frederiksberg Hospital, Denmark) and Dr. Soe (Gentofte Hospital, Denmark). All human materials were obtained with informed consent from donors or close relatives, and the approval of the relevant local ethical committees BioCat Ge, personal communication; Cambridge BioSciences, supplier information: Tissue Supply Network (www.bioscience.co.uk). The Dr. Bliddal / Soe sample was obtained under ethical permission No. H-4- 2009-117. The following antibodies were used: mouse monoclonal anti-human C5aR (R&D Systems, MAB3648 clone 347214 (lgG2a)). The mouse lgG2a isotype specific control (Dako, X0943, clone DAK-GO5). Biotin conjugated Donkey anti-mouse Jackson ImmunoReseach (715-065-150).
[000250] Immunohistochemistry was performed as follows. The sections were deparaffinized in xylene and rehydrated in decreasing concentrations of alcohols. The antigen extraction was performed in Tris-EGTA buffer (10 mM; 0.5 mM), pH 9.0 in a microwave oven for 15 min. Endogenous peroxidase activity was blocked with 3% H2O2, and endogenous biotin was blocked by incubation with blocking solutions of Avidin and Biotin for 10 min, respectively, according to the manufacturer. Non-specific binding was blocked by incubation with TBS containing 3% skim milk, 7% donkey serum, 3% human serum, and 3.2 mg / ml of Poly-L-Lysine (PLL) for 30 min. The primary and secondary antibodies were diluted in a Tris buffer containing 0.5% skim milk, 7% donkey serum and 3% human serum, and incubation was carried out overnight at 4 ° C, and 60 min at room temperature, respectively. The first amplification step was performed by incubation with the ABC peroxidase Vectastain kit, diluted in 0.1 M Tris-HCI Buffer (pH 7.5) containing 0.5% Du Ponto blocking reagent (TNB) for 30 min, followed by a second amplification step with incubation in biotinylated tiramide for 6 min. The final amplification was carried out by an additional incubation with the ABC peroxidase Vectastain kit, diluted as described above for 30 min. The chromogenic reaction was achieved with benzamine diamine. The cores were counterstained with hematoxylin and the sections were rehydrated, cleared in xylene and assembled with Eukitt. The evaluation of TMAs for the expression of C5aR protein in RA, OA and normal synovium was performed blind to the observer. An Olympus BX51 microscope equipped with a DP70 digital camera (Olympus Denmark A / S; Ballerup, Denmark) was used to evaluate the sections. Results
[000251] C5aR-immunopositive cells were found mixed in lymphoid aggregates in the synovial sub-lining layer in 8 out of 10 patients with psoriatic arthritis, and in the stroma of 10 out of 10 patients with psoriatic arthritis. Controls did not show any C5aT staining in these synovial compartments (0/5). C5aR-immunopositive synoviocytes were detected in the coating layer cells in controls 4 out of 5, as well as in 10 out of 10 patients with psoriatic arthritis. The results are summarized in Table 8 below.

[000252] Table 8. Detection of C5aR + cells in the normal synovium and synovium of patients with psoriatic arthritis. P-value (Fischer's exact test) for the difference between C5aR expression in patients with psoriatic arthritis compared to the normal synovium: 0.007 (lymphoid aggregates) and 0.0003 (stroma). Example 11. Inhibition of synovial fluid-induced neutrophil migration of patients with psoriatic arthritis by anti-C5aR.
[000253] Neutrophil Granulocyte Migration Assay (Chemotaxis)
[000254] The potency of the antibodies to inhibit hC5a-dependent migration of human neutrophil granulocytes (human PMNs (polymorphonuclear leukocytes)) was analyzed in a Boyden chamber assay using BD FluoroBlok 96-well insertion systems.
[000255] Human PMNs were obtained from human blood samples inserted in vials containing EDTA. Blood cells were separated by centrifuging blood (4 parts) through a Ficoll-Paque PLUS gradient (GE Health Care) (3 parts) for 30 min (400 x g) at room temperature. The PMN-containing layer was suspended in PBS (phosphate-buffered saline) containing dextran-500 (Sigma) for 1 h to remove contaminating erythrocytes. The supernatant was centrifuged for 5 min (250 x g) at room temperature and the remaining erythrocytes were osmotically lysed using 0.2% NaCI for 55 s. The solution was made isotonic by 1.2% NaCI + PBS and centrifuged at 250 x g for 5 min, before the osmotic lysis was repeated. After centrifugation, PMNs were resuspended in the reaction mixture (RM): HBSS (cat. No. 14175 Gibco) contains 137 mM NaCI, 5.3 mM KCI, 0.33 mM Na2HPO4, 4mM NaHCOs, 4HM KH2PO4 0.44 mM, 5 mM glucose; supplemented with 0.4 mM MgSθ4 * 7H2θ, 0.5 mM MgCh, 0.5 mM CaCh, 20 mM HEPES. Cell density was determined by NucleoCounter (Chemometec). The PMN suspension contained> 95% neutrophils, as assessed by microscopy of colored samples with Giemsa.
[000256] PMNs loaded: calcein, AM, (Fluka) was dissolved in DMSO (Dimethyl sulfoxide) and diluted 1,000X in cell RM (2 x 106 cells per ml) to result in a concentration of 10 pM. The suspension was incubated for 30 min in an incubator at 37 ° C and then washed 3 times with RM to remove excess calcein. Finally, the cells were resuspended in RM (4 x 10 6 cells / ml).
[000257] Human synovial fluid (FS) was obtained from 2 patients with psoriatic arthritis by knee puncture. After removing cells by centrifugation, the samples were frozen and stored at -80 ° C. For migration experiments, the samples were thawed and diluted 2X using RM containing 0.2% EDTA.
[000258] The migration was evaluated by the Boyden chamber technique using 96 wells with pore size of 3 pm FluoroBlok® (cat. No. 351161.BD Falcon (WVR)). The upper chamber, that is, the inserts containing Fluoroblok membrane, was coated with human fibrinogen (cat. No. F3879-1G, Sigma) in 1 mg / ml PBS at 37 ° C for two hours. After washing, the membranes were blocked with a solution containing 2% bovine serum albumin (BSA), in PBS. After another wash using RM, 105 PMNs loaded with calcein with or without hC5aR-antibodies (100 pg / ml) were added to each well and placed in the recipient plate (lower chamber) containing the control solution or the chemoattractive solution (hC5a (Sigma, or synovial fluid samples)). Each group comprised 4 to 6 cavities. The quantification of cell migration is achieved by measuring the fluorescence of cells in the lower chamber. As the FluoroBlok membrane effectively blocks the passage of light from 490 to 700 nm, the fluorescence of cells that did not enter the lower chamber is not detected at 485/530 nm. The plate was read at excitation / emission wavelengths of 485/538 nm, 37 ° C every 5 min for 60 min in a fluorescence plate reader with lower reading capabilities (SpectraMax, Molecular Devices, or Fluoroscan, Thermo Labsystems ).
[000259] The migration was evaluated by fluorescence values in 60 min expressed as relative fluorescence values. In Table 9, migration in the presence of an antibody isotype is set at 100% and the ability of the anti-C5aR antibody to inhibit migration is calculated. The migration was clearly attenuated by the hC5aR antibody. The migration produced by 10 nM hC5a was inhibited by 83%. The values for the three FS samples were: 15%, 70% and 48%. The results demonstrate that the C5aR antibody inhibited the chemoattractive effect of FS from patients with psoriatic atritis.

[000260] Table 9. Migration of PMNs in response to hC5a or synovial fluid from three patients with psoriatic attrition and their inhibition by the hC5aR antibody (antibody Ref. Q). All values are normalized for detected migration when incubated with antibody isotype. Example 12. C5aR expressing in the intestine of patients with Crohn's disease and ulcerative colitis
[000261] Samples of intestinal tissue within normal limits (n = 14), from patients with ulcerative colitis (n = 21) and Crohn's disease (n = 25) were obtained from Cambridge Bioscience (Cambridge, UK). All human materials were obtained with informed consent from donors or close relatives, and approval from relevant local ethical committees Cambridge BioSciences, supplier information: Tissue supply network (www.bioscience.co.uk). The antibodies used and the immunohistochemical protocol as described in Example 9. Semi-quantitative score
[000262] C5aR-immunopositive (C5aR +) cells were semiquantitively classified as follows:
[000263] The lymphoid compartments associated with the mucosa were individually classified: Mucosa (M): intraepithelial lymphocyte (IEL) compartment (superficial epithelium), lamina propria, and follicle-associated epithelium (FAE). Submucosa (SM): isolated lymphoid follicles (solitary) (ILF), Peyer plaques (ileum) colonic ZIEL (colon) and isolated infiltrating lymphocytes. External Muscle (ME): isolated infiltrating lELs and lymphocytes. Each compartment was rated on a scale from 0 to 4: 0, no; 1, few; 2, moderate; 3, many, and 4, abundant numbers of C5aR + cells. An accumulated score was calculated for each intestinal layer (M, SM, ME) and in total (M + SM + ME) for the entire intestine. Max score: M = 12, SM = 12, ME = 8 and for the entire intestine 32. The semiquantitative score of immunohistochemical data for C5aR protein expression was analyzed by Kruskal-Wallis test with Dunn's multiple comparisons test in GraphPad Prism 5. P <0.05 was considered significant. Results
[000264] C5aR-positive neutrophils and myeloid cells were found in the intraepithelial lymphocyte compartment, in the epithelium associated with the follicle and as solitary cells in the lamina propria of the mucosa in 23 of the 25 patients with CD, 19 of the 21 patients with UC and in 7 of the 14 normal intestinal samples (P values (Fisher's exact test) 0.005 and 0.015, respectively). In addition, C5aR-positive cells were found in Peyer plaques / colonic lymphoid follicles; isolated lymphoid follicles (solitary) and as solitary submucosa cells in 21 of the 25 patients with CD and 18 of the 21 patients with UC compared to 7 of the 14 normal intestinal samples (P values (Fisher's exact test) 0.03 and not significant, respectively). Finally, C5aR-positive cells were found infiltrating the external muscle of patients with CD and UC, as well as in the normal intestine. The results are shown in figure 6 and summarized in Table 10. Based on the semiquantitative analysis, it was concluded that C5aR has significantly higher expression in the intestine from patients with CD (P <0.01) and UC (P <0 , 05) compared to the normal intestine in the entire intestinal wall, for example, score accumulated over the three intestinal layers (mucosa, submucosa, and external muscle).

[000265] Table 10. Summary of C5aR expression in the intestine of patients with Crohn's disease and ulcerative colitis compared to the normal intestine.
[000266] While certain features of the invention have been illustrated and described here, many modifications, substitutions, changes, and equivalents will now occur to those skilled in the art. It is understood then that the attached modalities are intended to cover all such modifications and changes as they are within the true spirit of the invention.

权利要求:
Claims (12)
[0001]
1. C5aR-binding antibody, characterized by the fact that the variable region of the heavy chain of said antibody comprises a sequence CDR1, CDR2 and CDR3, wherein said sequence CDR1 comprises SEQ ID NO: 1,9, 17 or 25, and / or wherein said CDR2 sequence comprises SEQ ID NO: 2, 10, 18 or 26, and / or wherein said CDR3 sequence comprises SEQ ID NO: 3, 11, 19 or 27; and wherein the variable region of the light chain of said antibody comprises a sequence CDR1, CDR2 and CDR3, wherein said sequence CDR1 comprises SEQ ID NO: 5, 13, 21 or 29, and / or wherein said sequence of CDR2 comprises SEQ ID NO: 6, 14, 22 or 30, and / or wherein said CDR3 sequence comprises SEQ ID NO: 7, 15, 23 or 31.
[0002]
2. Antibody, according to claim 1, characterized by the fact that it is selected from: a. antibody in which the heavy chain variable region CDRs comprise SEQ ID NO: 1,2 and 3 and / or insertion (s) and where the variable light chain CDRs comprise SEQ ID NO: 5, 6 and 7, b. antibody in which the heavy chain variable region CDRs comprise SEQ ID NO: 9, 10 and 11 and where the variable light chain CDRs comprise SEQ ID NO: 13,14 and 15, c. antibody in which the heavy chain variable region CDRs comprise SEQ ID NO: 17,18 and 19 and where the variable light chain CDRs comprise SEQ ID NO: 21,22 and 23, d. antibody in which the heavy chain variable region CDRs comprise SEQ ID NO: 25, 26 and 27 and where the variable light chain CDRs comprise SEQ ID NO: 29, 30 and 31.
[0003]
3. Antibody according to claim 1 or 2, characterized in that the variable region of the heavy chain of said antibody comprises a sequence at least 80, 85, 90 or 94% identical to SEQ ID NO: 4, 12, 20 or 28, and / or wherein the variable region of the light chain of said antibody comprises a sequence at least 80, 85, 90 or 94% identical to SEQ ID NO: 8, 16, 24 or 32.
[0004]
Antibody according to any one of claims 1 to 3, characterized in that the antibody is a human antibody.
[0005]
Antibody according to any one of claims 1 to 4, characterized in that said antibody binds to human C5aR and, preferably, to the 2nd extracellular loop of human C5aR.
[0006]
6. Antibody according to any one of claims 1 to 5, characterized by the fact that the affinity of the antibody measured by the ligand binding competition assay in neutrophils is below 0.80 nM.
[0007]
Antibody according to any one of claims 1 to 6, characterized in that the antibody significantly inhibits or reduces the binding of C5a to C5aR.
[0008]
8. Antibody according to any one of claims 1 to 7, characterized in that the antibody significantly inhibits the migration of human neutrophils in vitro.
[0009]
Antibody according to any one of claims 1 to 8, characterized in that the Fc region is modified by point mutations in the amino acid sequence and has reduced binding affinity to one or more Fcy receptors compared to the sequences reference IgG 1, lgG2, lgG4 or lgG4 I G2 Fc, as defined by SEQ ID NO 33, 34, 35 and 36, respectively.
[0010]
Antibody according to any one of claims 1 to 13, characterized in that the antibody does not significantly induce ADCC, CDC and / or neutrophil phagocytosis in vitro.
[0011]
11. Antibody according to any one of claims 1 to 10, characterized by the fact that the Fc region is IgG 1, with one or more of the following groups of point mutations: N297Q and / or L234A and L235E and / or G236R and L328R and / or N297Q, L234A and L235E and / or N297Q, L234A, L235E and G237A and / or L234A, L235E, G237A, A330S and P331S.
[0012]
12. Use of an antibody, as defined in any of claims 1 to 13, characterized by the fact that it is for the preparation of a pharmaceutical composition for treating an immune disease or disorder, such as rheumatoid arthritis (RA), psoriatic arthritis , systemic lupus erythematosus (SLE), lupus nephritis, inflammatory bowel disease (Dll), or irritable bowel syndrome.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112013031198B1|2020-10-20|c5ar binding antibody and its use

---

US10711061B2|2020-07-14|Antibodies against canine PD-1

---

KR102366076B1|2022-02-21|Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof

---

CN107474133B|2021-10-15|Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use

---

DK2475684T3|2017-03-06|HUMAN HIGH-EFFICIENCY ANTIBODIES AGAINST HUMAN PROTEASE-ACTIVATED RECEPTOR-2

---

KR102047248B1|2019-11-21|Selective elimination of erosive cells

---

KR20180030931A|2018-03-26|Humanized anti-CCR7 receptor antibody

---

KR20150013935A|2015-02-05|Antibody against transporter and use thereof

---

ES2831303T3|2021-06-08|Therapeutic antibodies

---

MX2013013911A|2014-01-24|Therapeutic antibodies.

同族专利:

---

公开号 | 公开日

---

JP6416177B2|2018-10-31|

---

TWI564305B|2017-01-01|

---

JP2017081941A|2017-05-18|

---

PL3424953T3|2021-01-25|

---

US20130004514A1|2013-01-03|

---

US10323097B2|2019-06-18|

---

PT3424953T|2020-11-03|

---

EP2718322B1|2018-08-08|

---

IL229254A|2017-09-28|

---

EP3798230A1|2021-03-31|

---

JP6141834B2|2017-06-07|

---

ES2693647T3|2018-12-13|

---

EP2718322A1|2014-04-16|

---

TW201311724A|2013-03-16|

---

US20210238300A1|2021-08-05|

---

IL229254D0|2014-01-30|

---

US20130295116A1|2013-11-07|

---

RU2616881C2|2017-04-18|

---

US20200017599A1|2020-01-16|

---

US10882916B2|2021-01-05|

---

KR101978757B1|2019-05-15|

---

DK2718322T3|2018-12-03|

---

EP3424953A1|2019-01-09|

---

US8846045B2|2014-09-30|

---

CA2838497A1|2012-12-13|

---

CN103596982A|2014-02-19|

---

JP2014523408A|2014-09-11|

---

BR112013031198A8|2018-01-16|

---

WO2012168199A1|2012-12-13|

---

AU2012266487A1|2013-11-21|

---

US8613926B2|2013-12-24|

---

BR112013031198A2|2016-11-29|

---

RU2013155029A|2015-07-20|

---

DK3424953T3|2020-11-02|

---

KR20140036261A|2014-03-25|

---

PL2718322T3|2019-07-31|

---

CN103596982B|2016-11-02|

---

EP3424953B1|2020-08-05|

---

AU2012266487B2|2016-12-08|

---

US20170073421A1|2017-03-16|

---

US20150044231A1|2015-02-12|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

NL154598B|1970-11-10|1977-09-15|Organon Nv|PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.|

---

US3901654A|1971-06-21|1975-08-26|Biological Developments|Receptor assays of biologically active compounds employing biologically specific receptors|

---

US4098876A|1976-10-26|1978-07-04|Corning Glass Works|Reverse sandwich immunoassay|

---

US4704362A|1977-11-08|1987-11-03|Genentech, Inc.|Recombinant cloning vehicle microbial polypeptide expression|

---

US4568649A|1983-02-22|1986-02-04|Immunex Corporation|Immediate ligand detection assay|

---

US4676980A|1985-09-23|1987-06-30|The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services|Target specific cross-linked heteroantibodies|

---

EP0832981A1|1987-02-17|1998-04-01|Pharming B.V.|DNA sequences to target proteins to the mammary gland for efficient secretion|

---

JPH02262599A|1989-01-03|1990-10-25|Merck & Co Inc|Purified c5a receptor from human polymorphonuclear leukocyte|

---

WO1991000360A1|1989-06-29|1991-01-10|Medarex, Inc.|Bispecific reagents for aids therapy|

---

US5633076A|1989-12-01|1997-05-27|Pharming Bv|Method of producing a transgenic bovine or transgenic bovine embryo|

---

US5284746A|1990-02-08|1994-02-08|Zymogenetics, Inc.|Methods of producing hybrid G protein-coupled receptors|

---

US5194594A|1990-09-07|1993-03-16|Techniclone, Inc.|Modified antibodies|

---

US5173414A|1990-10-30|1992-12-22|Applied Immune Sciences, Inc.|Production of recombinant adeno-associated virus vectors|

---

EP0586505A1|1991-05-14|1994-03-16|Repligen Corporation|Heteroconjugate antibodies for treatment of hiv infection|

---

EP0672068A4|1992-09-25|1997-02-26|Commw Scient Ind Res Org|Target binding polypeptide.|

---

DE69329503T2|1992-11-13|2001-05-03|Idec Pharma Corp|Therapeutic use of chimeric and labeled antibodies directed against a differentiation antigen, the expression of which is restricted to human B lymphocyte, for the treatment of B cell lymphoma|

---

US5514555A|1993-03-12|1996-05-07|Center For Blood Research, Inc.|Assays and therapeutic methods based on lymphocyte chemoattractants|

---

US5480974A|1993-06-18|1996-01-02|The Scripps Research Institute|Antibodies to human C5a receptor|

---

US5827690A|1993-12-20|1998-10-27|Genzyme Transgenics Corporatiion|Transgenic production of antibodies in milk|

---

US20010036650A1|1994-08-16|2001-11-01|Human Genome Sciences, Inc.|C5a receptor|

---

JPH08109200A|1994-08-19|1996-04-30|Takeda Chem Ind Ltd|Anti-c5a receptor antibody, its production and use|

---

US5861272A|1995-06-02|1999-01-19|Human Genome Sciences, Inc.|C5A receptor|

---

WO1996039511A2|1995-06-05|1996-12-12|Incyte Pharmaceuticals, Inc.|A C5a-LIKE SEVEN TRANSMEMBRANE RECEPTOR|

---

EP2305027B1|1996-12-03|2014-07-02|Amgen Fremont Inc.|Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom|

---

WO1998033908A1|1997-01-31|1998-08-06|Incyte Pharmaceuticals, Inc.|Human c5a-like receptor|

---

AUPO591797A0|1997-03-27|1997-04-24|Commonwealth Scientific And Industrial Research Organisation|High avidity polyvalent and polyspecific reagents|

---

WO1998048837A1|1997-04-30|1998-11-05|Enzon, Inc.|Polyalkylene oxide-modified single chain polypeptides|

---

US8007798B2|1997-11-21|2011-08-30|Genentech, Inc.|Treatment of complement-associated disorders|

---

TWI327597B|2001-08-01|2010-07-21|Centocor Inc|Anti-tnf antibodies, compositions, methods and uses|

---

AU3119402A|2000-11-07|2002-05-21|Inst Genetics Llc|Novel g protein-coupled receptor protein and nucleic acid molecules and uses therefor|

---

WO2002061087A2|2000-12-19|2002-08-08|Lifespan Biosciences, Inc.|Antigenic peptides, such as for g protein-coupled receptors , antibodies thereto, and systems for identifying such antigenic peptides|

---

JP2005505236A|2000-12-19|2005-02-24|アルトーバイオサイエンスコーポレイション|Transgenic animals including humanized immune system|

---

JP2007534631A|2003-10-28|2007-11-29|ノボ　ノルディスク　アクティーゼルスカブ|Laminin-5γ2 binding peptides, related compositions and uses thereof|

---

US20030133939A1|2001-01-17|2003-07-17|Genecraft, Inc.|Binding domain-immunoglobulin fusion proteins|

---

US7432356B2|2001-08-17|2008-10-07|Genentech, Inc.|Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b|

---

US7193070B2|2001-09-27|2007-03-20|Merck & Co., Inc.|Isolated DNA molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods|

---

US7241444B2|2002-01-18|2007-07-10|Pierre Fabre Medicament|Anti-IGF-IR antibodies and uses thereof|

---

EP1476469B1|2002-01-25|2015-11-18|Novo Nordisk A/S|Monoclonal antibodies against extracellular loops of c5ar|

---

AU2003217912A1|2002-03-01|2003-09-16|Xencor|Antibody optimization|

---

JP2006513702A|2002-09-09|2006-04-27|ヌラインコーポレーティッド|G protein-coupled receptor and use thereof|

---

US8101720B2|2004-10-21|2012-01-24|Xencor, Inc.|Immunoglobulin insertions, deletions and substitutions|

---

AU2002952086A0|2002-10-16|2002-11-07|The University Of Queensland|Treatment of osteoarthritis|

---

MXPA05005921A|2002-12-02|2005-10-19|Abgenix Inc|Antibodies directed to tumor necrosis factor and uses thereof.|

---

US7807389B2|2003-03-14|2010-10-05|University Of Rochester|Methods and compositions related to joint inflammation diseases|

---

US20060240436A1|2003-03-17|2006-10-26|Stefan Golz|Diagnostics and therapeutics for diseases associated with complement component 5a receptor |

---

US8071839B2|2003-12-24|2011-12-06|G2 Inflammation Pty Ltd|Transgenic mouse comprising a polynucleotide encoding human or humanized C5aR and methods of production and use|

---

EP1586583A3|2004-04-16|2005-11-16|Alligator Bioscience AB |Compounds that block C5a complement receptor and their use in therapy|

---

NZ561883A|2005-03-23|2010-11-26|Genmab As|Antibodies against CD38 for treatment of multiple myeloma|

---

WO2007055374A1|2005-11-14|2007-05-18|Mitsubishi Tanabe Pharma Corporation|Therapeutic agent for osteoporosis|

---

JP2010501165A|2006-08-22|2010-01-21|ジーツーインフラメイションプロプライエタリーリミテッド|Antibody production method|

---

CN104059149B|2006-08-22|2017-04-12|诺沃诺蒂斯克股份有限公司|Anti-C5aR antibodies with improved properties|

---

WO2008030564A2|2006-09-08|2008-03-13|Verenium Corporation|Aglycosylated antibodies and methods of making and using those antibodies|

---

JP5314033B2|2007-10-22|2013-10-16|メルクセローノソシエテアノニム|Single IFN-beta fused to mutant IgG Fc fragment|

---

JP2011515073A|2008-02-20|2011-05-19|ジーツーインフラメイションプロプライエタリーリミテッド|Humanized anti-C5aR antibody|

---

WO2009149081A1|2008-06-02|2009-12-10|Novelmed Therapeutics, Inc.|Method for treating inflammatory conditions|

---

US20090324585A1|2008-06-12|2009-12-31|The Trustees of the Leland Standford Junior University|Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis|

---

WO2010000864A1|2008-07-04|2010-01-07|Novo Nordisk A/S|Method for producing monoclonal antibodies|

---

SI2381778T1|2008-12-22|2016-10-28|Chemocentryx, Inc.|C5ar antagonists|

---

WO2011100477A2|2010-02-10|2011-08-18|Taiga Biotechnologies, Inc.|Antibodies and processes for preparing the same|

---

EP3409289B1|2010-02-26|2020-09-30|Novo Nordisk A/S|Stable antibody containing compositions|

---

US20130136733A1|2010-05-28|2013-05-30|Novo Nordisk A/S|Stable Multi-Dose Compositions Comprising an Antibody and a Preservative|

---

EP2588499B1|2010-06-30|2020-04-08|Novo Nordisk A/S|Antibodies that are capable of specifically binding tissue factor pathway inhibitor|

---

US20130183280A1|2010-07-15|2013-07-18|Novo Nordisk A/S|Stabilized factor viii variants|

---

WO2012088247A2|2010-12-22|2012-06-28|Medimmune, Llc|Anti-c5/c5a/c5adesr antibodies and fragments|

---

BR112013031198B1|2011-06-06|2020-10-20|Novo Nordisk A/S|c5ar binding antibody and its use|

---

CN105392803B|2013-05-08|2019-12-06|诺和诺德股份有限公司|Use of C5aR antagonists|BR112013031198B1|2011-06-06|2020-10-20|Novo Nordisk A/S|c5ar binding antibody and its use|

---

US9657105B2|2013-03-15|2017-05-23|City Of Hope|CD123-specific chimeric antigen receptor redirected T cells and methods of their use|

---

WO2015035606A1|2013-09-13|2015-03-19|Beigene, Ltd.|Anti-pd1 antibodies and their use as therapeutics and diagnostics|

---

AU2014376328A1|2014-01-13|2016-07-21|Christine E. BROWN|Chimeric antigen receptorshaving mutations in the Fc spacer region and methods for their use|

---

US20170107294A1|2014-03-21|2017-04-20|Nordlandssykehuset Hf|Anti-cd14 antibodies and uses thereof|

---

EP3160505A4|2014-07-03|2018-01-24|BeiGene, Ltd.|Anti-pd-l1 antibodies and their use as therapeutics and diagnostics|

---

SG11201700496WA|2014-07-22|2017-02-27|Cb Therapeutics Inc|Anti-pd-1 antibodies|

---

US10435470B2|2014-08-05|2019-10-08|Cb Therapeutics, Inc.|Anti-PD-L1 antibodies|

---

US20170328898A1|2014-10-31|2017-11-16|Cell Trend GmbH|Diagnosis of an autoimmune disease using detection of antibodies directed against c5a-receptor|

---

EP3371227B1|2015-11-04|2022-02-23|City of Hope|Chimeric antigen receptors targeting her2|

---

JP2019509014A|2015-11-23|2019-04-04|イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ．|CD39 vascular isoform targeting agent|

---

RU2018122452A3|2015-11-25|2020-05-13|

---

CN106957366B|2016-01-12|2022-02-01|上海昀怡健康科技发展有限公司|C5aR antibody and preparation method and application thereof|

---

US10053515B2|2016-01-22|2018-08-21|Merck Sharp & Dohme Corp.|Anti-coagulation factor XI antibodies|

---

CN109476758A|2016-06-14|2019-03-15|默沙东公司|Anti- plasma thromboplastin antecedent antibody|

---

AU2017293423A1|2016-07-05|2019-01-31|Beigene, Ltd.|Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer|

---

WO2019034580A1|2017-08-14|2019-02-21|Morphosys Ag|Humanized antibodies for cd3|

---

WO2019092148A1|2017-11-10|2019-05-16|Innate Pharma|Antibodies with functionalized glutamine residues|

---

US20190300610A1|2018-03-29|2019-10-03|Hummingbird Bioscience Pte. Ltd.|Vista antigen-binding molecules|

---

EP3891186A1|2018-12-05|2021-10-13|MorphoSys AG|Multispecific antigen-binding molecules|

---

SG11202108761YA|2019-03-14|2021-09-29|Morphosys Ag|Antibodies targeting c5ar|

---

WO2021146320A1|2020-01-13|2021-07-22|Visterra, Inc.|Antibody molecules to c5ar1 and uses thereof|

---

GB2595299A|2020-05-21|2021-11-24|Mabsolve Ltd|Modified immunoglobulin FC regions|

---

WO2022033981A1|2020-08-12|2022-02-17|Innate Pharma|Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab|

法律状态:
2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2018-04-03| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2019-07-16| B07E| Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2020-03-17| B07A| Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]|

---

2020-08-11| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2020-10-20| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/06/2012, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

EP11168787.7|2011-06-06|

---

EP11168787|2011-06-06|

---

US201161505137P| true| 2011-07-07|2011-07-07|

---

US61/505,137|2011-07-07|

---

EP12159172|2012-03-13|

---

EP12159172.1|2012-03-13|

---

PCT/EP2012/060524|WO2012168199A1|2011-06-06|2012-06-04|Therapeutic antibodies|

---